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Abstract 
 
The role of the microbiology laboratory is (1) to provide infection control information, so that 
highly transmissible isolates may be identified and appropriate control measures instigated as 
rapidly as possible and (2) to provide adequate information to the clinician enabling correct 
antibiotic choices to be made, particularly in the critically ill. Microbiological data is by 
definition slow as it is culture dependent: this study focused on the development of genetic, 
culture-independent methods for detection of resistance in nosocomial pathogens that could 
be introduced into the routine microbiology department and would fit into the routine 
workflow with a consequent reduction in time to result. 
Initially a duplex real-time polymerase chain reaction was developed for the rapid 
identification and detection of S. aureus and methicillin-resistance. This was optimised for 
immediate as-needs testing of positive blood cultures signalling with “Gram positive cocci, 
possibly staphylococcus” evident on Gram stain, on a random access real-time PCR platform. 
This technology, allowing early identification of S. aureus and its susceptibility to methicillin, 
by simple automated methodology, may soon become the standard for all microbiology 
laboratories servicing the critically ill. 
The second part of the study involved the development of a selective broth and 
multiplex PCR for detection of three important nosocomial isolates at this institution, 
methicillin-resistant S. aureus (MRSA), carbapenem-resistant Enterobacteriaceae, and multi-
resistant Acinetobacter baumannii (MRAB). A multiplex PCR using four primer sets was 
designed to detect low colonisation levels of these isolates after overnight incubation in 
selective broth, significantly reducing the time to result and associated costs. This potentially 
useful epidemiological screening tool is practical, reproducible and sensitive with the 
potential of moving to an automated test (using real-time PCR, for example) in the future. The 
availability of early negative results judged by simple visual scanning (or by densitometry), 
means that the result is less operator-dependent, potentially reducing error rate. 
The last part of the study dealt with an important resistance phenotype, 
aminoglycoside resistance. There had been no recent comprehensive local surveys performed 
to determine the frequency of aminoglycoside resistance amongst the Enterobacteriaceae, or 
to identify the genetic determinants and their transmissibility. The isolates collected for the 
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study were all resistant to at least one of gentamicin, tobramycin or amikacin. Identification of 
integron cassette arrays and use of specific internal primers identified at least one genetic 
determinant for gentamicin and tobramycin resistance in 22 of 23 isolates. Three isolates had 
two aminoglycoside resistance genes, and three isolates had three aminoglycoside resistance 
genes identified (Table 6.1). Transferable gentamicin-resistant plasmids were predominant 
amongst Klebsiella spp., but less so amongst Enterobacter spp. and E. coli. Gentamicin-
resistant Klebsiella spp. were often ESBL positive, the genetic determinants of which were 
typically co-transferred on a conjugative plasmid. The importance of screening at a local level 
was demonstrated by the unexpected predominance of aac(6')-IIc amongst Enterobacter spp. 
and the detection of a new gene (aac(6')-LT). 
This part of the study has provided an understanding of the primary aminoglycoside 
resistance genes present in the local setting and their association with other resistances. This 
knowledge will allow development of assays for patient screening (clinical isolates and 
colonising flora), to better understand the epidemiology of aminoglycoside resistance and to 
allow better choice of antibiotic therapy related to presence or absence of these genes. 
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1 Chapter 1 
 
 
 
1.1 Introduction 
 
 
1.1.1 Emerging Antibiotic Resistance 
The isolation of natural products with antibacterial activity from microbial sources 
originated from the original discovery in 1928 of penicillin, produced by a fungus, 
Penicillium (Fleming 1929). Researchers then discovered antibacterial activity in other 
microorganisms, which provided many of the well-known antibiotic classes used today. 
Since the discovery of naturally occurring antibiotics, resistance has rapidly emerged, 
often soon after their introduction into clinical use began. Further antibiotics, either 
semi-synthetics derived from natural products (e.g. ceftriaxone) or artificially 
synthesised (e.g. sulphonamide), were introduced to deal with the rapid onset of 
resistance but resistance to these and other antimicrobials is now common. During the 
past century, the development of new antimicrobial agents has been the most successful 
strategy against the emergence of specific resistance (reviewed by Canton et al. 2003), 
however, few new antibiotics effective against Gram-negative bacteria are being 
developed (reviewed by Richards 2005). The financial gain to be made from such a 
product has to be weighed against the considerable cost of its development and animal 
and human clinical trials (reviewed by MacDougall and Polk 2005). 
 
1.2 Resistance in the community 
Bacterial resistance in community isolates is thought to be largely due to antibiotic 
over-prescribing (reviewed by Steinke and Davey 2001) and increasing dissemination 
of antibiotic-resistant community isolates is associated with treatment failure (reviewed 
by Paterson 2006). 
Use of antibiotics as growth promoters in the meat industry has also been 
implicated in the transfer of antibiotic resistance to humans via the food chain (Coque et 
al. 1996). In Europe, extensive use of avoparcin as a growth promoter in food 
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production animals has been implicated in the dissemination of van resistance genes in 
the community and their emergence in hospital outbreaks (Woodford 2005). Use of 
another important antibiotic group, the fluoroquinolones, in the treatment and 
prophylaxis of food animals is considered responsible for the emergence of strains of 
Salmonella with reduced susceptibility to these antibiotics (Molbak et al. 2002). 
 
1.3 Resistance in the healthcare setting 
Infections in the health care setting are those infections defined as having been acquired 
by in-patients in hospitals and nursing homes as well as those patients attending 
outpatient clinics such as dialysis and oncology centres. There have been a number of 
reviews on nosocomial infections, all agreeing that resistance in the hospital setting is 
increasing and of serious concern (Farr et al. 2001; Canton et al. 2003; Diekema et al. 
2004; Lim and Webb 2005). There are two broad categories of acquisition of resistant 
organisms, the first being transfer of resistant (nosocomial) organisms via equipment, or 
health workers, broadly referred to as exogenous acquisition, (e.g. MRSA). The second 
mechanism is by antibiotic selection of resistant subpopulations within the patient's own 
flora, and is termed endogenous acquisition. An alternate mechanism of resistance 
acquisition is the transfer of genetic determinants such as plasmids amongst different 
genera of bacteria, with outbreaks difficult to detect as they are plasmid-specific and the 
phenotype is conditional upon the bacterial context (Espedido et al. 2005).  
 
1.3.1 Risk factors for colonisation and infection with resistant bacteria  
Patients at high risk for acquisition of resistant bacteria are those that are seriously ill, 
experience prolonged hospital stays, have devices such as endotracheal tubes or urinary 
catheters in place, and have had prior heavy antibiotic use (Cisneros et al. 2005; 
Playford 2006). Opportunistic pathogens such as P. aeruginosa and Acinetobacter spp., 
well adapted to survival on inert surfaces such as catheters and medical equipment, play 
a major role in infection amongst severely ill long-term immobilised patients (reviewed 
by Lim and Webb 2005). The increasing problem of extended-spectrum β-lactamases 
(ESBLs) in Enterobacteriaceae is an excellent example of resistance evolution, and has 
been the subject of a number of recent publications and reviews (Paterson and Bonomo 
2005; Babic et al. 2006; Livermore and Woodford 2006; Paterson 2006). There is a 
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direct relationship between antibiotic use and emerging resistance and it has been 
suggested that restriction of some antibiotics, particularly 3rd generation cephalosporins, 
may reduce resistance and improve patient outcome (Rahal et al. 1998; Asensio et al. 
2000; Du et al. 2002).  
Although antibiotic choices are important considerations in reducing resistance 
(reviewed by Peterson 2005), resistance to a class of antibiotics is not necessarily 
initiated by exposure to that same class. Acquisition of, and increased colonisation by, 
vancomycin-resistant enterococci has been attributed to use of 3rd generation 
cephalosporins, to which they are intrinsically resistant (Bonten et al. 1998; Rice et al. 
2004), and colonisation with cefuroxime-resistant Enterobacteriaceae in a neonatal 
intensive care ward was attributed to ampicillin use rather than use of cefuroxime 
(Tullus et al. 1988). 
 
1.4 General eubacterial characteristics  
Bacteria may be divided into two groups (Gram-positive and Gram-negative) by their 
ability to retain the aniline dye crystal violet (C25H30CIN3) after treatment with a 
decolourising agent such as acetone. In Gram-positive bacteria, crystal violet is trapped 
in a thick cross-linked mesh-like peptidoglycan layer that surrounds the cell (Fig. 1.1). 
Gram-negative bacteria have a thin peptidoglycan layer, which does not retain crystal 
violet stain, and an outer membrane that contains lipopolysaccharides, phospholipids, 
and proteins (Fig. 1.1).  
 
 
 
 
 
 
 
 
Gram-negative Gram-positive 
 
 
Figure 1.1 Structure of Gram -positive and Gram-negative bacteria 
Source: Medical Microbiology (Murray et al. 1998). 
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1.4.1 
The Gram-negative bacterial cell also has a periplasmic space between the cytoplasmic 
and outer membranes containing transport, degradative and cell wall synthesis proteins. 
The outer membrane of Gram-negative bacteria acts as a permeability barrier to large 
molecules within which aqueous channels (porins), traversing the entire lipid bilayer, 
allow diffusion of molecules through the membrane.  
 
Gram-positive bacteria 
 
1.4.1.1 Staphylococcus aureus 
S. aureus is one of the most significant human pathogens, causing serious nosocomial 
and community infection in a variety of conditions, with frequent involvement in skin 
and soft tissue infections, postoperative infections and septicaemia. Moist environments 
such as the nose and perineum are colonised in about 30% of the population. S. aureus 
will successfully survive on drier surfaces or equipment, with the potential to infect or 
cross-colonise from this source (Livermore 2000). 
The main mechanism of resistance in S. aureus, emerging not long after the introduction 
of penicillin, was the production of a penicillinase that renders S. aureus resistant to 
penicillin. Methicillin came into clinical use in the 1960s and resistance to this 
antibiotic was detected shortly thereafter. High-level methicillin resistance in 
staphylococcus is encoded by the mecA gene, which produces an alternate penicillin 
binding protein (PBP-2a) that has less susceptibility to methicillin. Methicillin-resistant 
S. aureus (MRSA) are often resistant to multiple antibiotics, particularly in the 
nosocomial environment. 
Table 1.1 Primary resistance mechanisms in staphylococci  
Adapted from (Merlino 2004). 
Drug/class Function inhibited Drug target Mechanism of resistance 
 
β-lactams 
e.g. penicillin 
cephalothin 
 
Peptidoglycan 
synthesis 
 
Transpeptidases 
and 
carboxpeptidases 
 
Acquisition of β-lactamases 
and PBP2a 
Glycopeptides 
e.g. vancomycin 
teicoplanin 
 
Peptidoglycan 
synthesis 
Cell wall 
peptidoglycan 
Multiple mutations affecting 
peptidoglycan synthesis. 
Acquisition of vanA or vanB 
Fluoroquinolones 
e.g. ciprofloxacin 
 
DNA 
replication/transcription 
Topoisomerase 
IV and DNA 
gyrase 
Mutations in genes encoding 
topoisomerase IV and DNA 
gyrase NorA mediated efflux 
Rifamycins 
e.g. rifampicin 
Transcription RNA 
polymerase 
Mutations in rpoB subunit of 
RNA polymerase 
Fusidic acid Protein synthesis Elongation 
factor G (FusA) 
Mutations in fusA and 
acquisition of plasmid-
determined fusB mechanism 
 
Aminoglycosides 
e.g. gentamicin 
tobramycin 
amikacin 
 
Protein synthesis 30S ribosomal 
subunit 
Adenylation and 
phosphorylation by AAC(6')-
APH(2') inactivating enzyme 
Macrolides 
e.g. erythromycin 
Protein synthesis 50S ribosomal 
subunit 
Methylation of 23S rRNA 
following acquisition of erm 
determinants 
Oxazolidinone 
e.g. linezolid 
Protein synthesis 50S ribosomal 
subunit 
Mutation in 23S rRNA 
Streptogramins 
e.g. virginiamycin 
quinupristin/dalphopristin,  
Protein synthesis 50S ribosomal 
subunit 
Efflux by vgaA and vgaB 
determinants 
Acquisition of tetK (efflux) 
and tetM (ribosomal 
protection) determinants 
Tetracyclines 
e.g. tetracycline 
doxycycline 
Protein synthesis 30S ribosomal 
subunit 
Acquisition of mupA, 
encoding an alternative IRS. 
Mutations in ileS 
Mupirocin Inhibits isoleucyl tRNA 
synthesis therefore 
stopping protein 
synthesis. 
Isoleucyl tRNA 
synthesis (ileS) 
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1.4.1.2 Enterococci 
Enterococci are generally considered commensals of the gastrointestinal tract of humans 
and animals. Survival in the environment for extended periods of time is thought to 
allow their nosocomial spread (Noble 1978). Infections caused by the genus 
Enterococcus (most notably E. faecalis, which accounts for ~80% of all infections) 
include urinary tract infections, bacteremia, intra-abdominal infections, and endocarditis 
(Huycke et al. 1998). Therapy with antibiotics possessing little anti-enterococcal 
activity (e.g. cephalosporins) is a key predisposing factor leading to enterococcal 
colonisation and infection (reviewed by Chenoweth and Schaberg 1990). 
Resistance to ampicillin and vancomycin is relatively uncommon in E. faecalis 
while E. faecium shows increasing resistance to ampicillin, primarily due to the 
presence of a low affinity PBP (PBP5). Increasing resistance to vancomycin is also 
observed since the discovery of vanA, encoding vancomycin resistance, in 1987 
(Huycke et al. 1998; Sauvage et al. 2002). There are now at least five acquired genes 
(vanA, vanB, vanD, vanE and vanG) and one intrinsic gene (vanC found in E. 
casseliflavus, and E. gallinarum) identified (Woodford 2005). The first vancomycin-
resistant enterococci (VRE) isolated in Australia was an E. faecium (vanB) in 1994, but 
since that date further isolates of E. faecium and E. faecalis, with vanA and vanB genes, 
have been identified (Bell et al. 1998). All vancomycin-resistant strains produce altered 
peptidoglycan pentapeptide precursors with decreased binding affinity for 
glycopeptides.  
 
1.4.2 Gram-negative bacteria 
 
1.4.2.1 Enterobacteriaceae  
The most medically important members of the Enterobacteriaceae include Escherichia, 
Enterobacter, Klebsiella, Citrobacter and Serratia spp. Many are normal colonisers of 
the healthy intestinal tracts of humans and animals and are mostly opportunistic 
pathogens, particularly in compromised patients. E. coli and other colonisers of the 
intestinal tract may cause urinary tract infections in healthy individuals. Uropathogenic 
strains (particularly E. coli) carry additional features such as adhesion fimbriae, which 
facilitate attachment to the urethral mucosa. (reviewed by Svanborg Eden et al. 1982 
(a); Svanborg Eden et al. 1982 (b)) Outbreaks may occur by exogenous dissemination 
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of clonal strains on medical equipment or the hands of medical personnel. Prior 
antibiotic use also may select for resistant subpopulations from the patient's endogenous 
intestinal flora leading to overgrowth and increased risk of infection (Tullus et al. 1988; 
Asensio et al. 2000).  
Efficient horizontal transfer of resistance genes between Enterobacteriaceae in 
the face of intensive selection pressure occurs readily, and has been demonstrated both 
in the laboratory in mating experiments and in patient’s colonising flora (Espedido et al. 
2005). Genes may be mobilised by plasmids and transposons, which are common in 
Enterobacteriaceae (reviewed by Liebert et al. 1999; Dionisio et al. 2002) and 
discussed later in this Chapter (see 1.9. Mechanisms of transfer of resistance). 
 
1.4.2.2 Pseudomonas spp. 
Pseudomonas spp. are widely distributed in nature and may be isolated from soil, water, 
plants, and animals or as a minor part of the normal microbial flora of humans. Their 
nutritional requirements are minimal, they are adaptable to a wide variety of physical 
conditions, and they are intrinsically resistant to many antibiotics at concentrations 
achievable in vivo. Hospitalised patients may have increased colonisation rates by these 
opportunistic pathogens, particularly in the context of burns, mechanical ventilation and 
antibiotic usage. P. aeruginosa is an opportunistic pathogen, capable of causing severe 
invasive disease in critically ill and immunocompromised patients (Deplano et al. 2005) 
and is consistently identified as one of the two most common pathogens causing 
nosocomial pneumonia (Richards et al. 1999), but rarely causes disease in a healthy 
person. Outbreaks are often linked to a specific source such as medical equipment, 
disinfectants, eye drops, dialysis fluids or hydrotherapy pools (Gustafson et al. 1983; 
Morrison and Wenzel 1984; Bottone and Perez 1993).  
The well recognised intrinsic antibiotic resistance in P. aeruginosa is due to 
the expression of chromosomally encoded efflux pumps (reviewed by Li and Nikaido 
2004) as well as low permeability through the outer membrane (Angus et al. 1982; 
Nicas and Hancock 1983). The outer membrane is unusual in that its non-specific porin, 
protein F, produces only a very low level of permeability in comparison with most other 
Gram-negative bacteria (Yoshimura and Nikaido 1982). All P. aeruginosa contain 
inducible chromosomal β-lactamases that confer resistance to cephalosporins, with up-
regulation of expression possible by mutation. P. aeruginosa may acquire genes 
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encoding additional resistance mechanisms under selective antibiotic pressure (Hocquet 
et al. 2003). Examples include acquisition of genes encoding ESBLs (Poirel et al. 2003) 
metallo-β-lactamases, or other enzymes (Poirel et al. 2000). Additionally, mutations 
may also occur in genes intrinsic to P. aeruginosa leading to increased expression of 
resistance determinants (Yoshida et al. 1990; Yokoyama et al. 2003). For example, all 
P. aeruginosa strains contain genes encoding the chromosomal β-lactamase, AmpC. 
Up-regulation of expression of the gene, resulting from mutation, may lead to resistance 
to cephalosporins. 
 
1.4.2.3 Acinetobacter  spp. 
Acinetobacter spp. are strictly aerobic non-fermenting coccobacilli, widely distributed 
in nature and the hospital environment (Getchell-White et al. 1989). Long-term survival 
on inanimate objects allows dissemination throughout hospitals, via equipment and 
staff, causing nosocomial bacteraemia, pneumonia, urinary-tract infections and wound 
infections (reviewed by Gales et al. 2001; Joly-Guillou 2005). 
A. baumannii is the most common nosocomial Acinetobacter species. It is 
considered a low-grade pathogen and is capable of remaining on or in the human body 
without causing infection. Its potential to cause unexpected outbreaks that are difficult 
to control, and its multi-resistant profile are what makes this organism of serious 
concern (reviewed byJoly-Guillou 2005). The adjusted mortality risk for Intensive Care 
patients infected by carbapenem-resistant Acinetobacter may be increased more than 
three-fold (Playford 2006). Outbreaks due to multi-resistant Acinetobacter may be due 
to dissemination of one clone (Hsueh et al. 2002) or a variety of clones (Cisneros et al. 
2005; Valenzuela et al. 2007). 
Nosocomial Acinetobacter spp. are characteristically multi-drug resistant 
(Cisneros et al. 1996). Resistance to β-lactams is often associated with chromosomally 
encoded cephalosporinases and plasmid-mediated penicillinases (Vila et al. 1993). 
Aminoglycoside resistance is usually due to acquisition of aminoglycoside-modifying 
enzymes (either in transposons and plasmids) (Shaw et al. 1989; Vila et al. 1993), and 
quinolone resistance is usually attributed to mutations in the DNA gyrase subunits 
(reviewed by Bergogne-Berezin and Towner 1996). Carbapenem resistance may be 
conferred by plasmid-mediated carbapenemases (Scaife et al. 1995) with altered 
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penicillin-binding proteins, loss of porins, and altered outer membrane permeability 
(Hancock 1998; Limansky et al. 2002; Fernandez-Cuenca et al. 2003). 
 
1.4.3 Clinically important antibiotics and their modes of activity 
The most important antibiotic mechanisms include inhibition of cell wall remodelling, 
interference with protein translation, interference with nucleic acid synthesis, and 
inhibition of folate metabolism (Table 1.2). Antibiotic activity and resistance is to some 
extent influenced by differences in the structure of Gram-positive and Gram-negative 
bacteria (Fig. 1.1). All bacterial cell walls contain a mucopolysaccharide component 
called peptidoglycan, the quantity and location of which varies between Gram-positive 
and Gram-negative bacteria. Peptidoglycan is essential for maintaining the rigidity of 
the cell wall to prevent the cell from rupturing and consists of long linear 
polysaccharide (glycan) chains cross-linked by peptide chains. The glycan strands are 
made up of alternating N-acetylmuramic acid and N-acetylglucosamine, the former 
having short peptide stems attached to it. Bacterial transpeptidases (detected as 
penicillin-binding proteins or PBPs) are essential enzymes that catalyse this cross-
linking step. Peptidoglycan production involves initial synthesis of precursors in the 
cytoplasm, transport of lipid-bound precursors across the cytoplasmic membrane, 
insertion of the glycan units into the cell wall, and lastly transpeptidation linking and 
maturation. Gram-positive bacteria with their peptidoglycan-rich cell wall and limited 
permeability are able to tolerate a harsh external environment and act as opportunistic 
pathogens. In Gram-negative bacteria, the periplasmic space is bounded on one side by 
the inner cell membrane and on the other by a thinner peptidoglycan layer containing 
outer membrane porins that may effectively exclude or allow entry of some substances, 
including antibiotics. Antibiotics may be altered during passage through the periplasm 
(e.g. by enzymes) affecting their penetration and ultimate activity inside the cytoplasmic 
membrane.  
 
1.4.3.1 Inhibitors of peptidoglycan synthesis 
Examples of antibiotics that act by inhibition of peptidoglycan synthesis are D-
cycloserine and bacitracin, which inhibit early stages of peptidoglycan synthesis. β-
lactams and glycopeptides act at the last two stages. β-lactam antibiotics bind to the 
PBPs at their D-alanyl-D-alanine binding pocket, inhibiting cross-bridge formation 
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whilst glycopeptides bind to D-alanyl-D-alanine residues of the murein monomer in the 
cytoplasmic membrane (reviewed by Hiramatsu 2001; McDermott et al. 2003).  
 
1.4.3.2 Inhibitors of nucleic acid metabolism 
Compounds that inhibit nucleic acid synthesis may interfere with either nucleotide 
synthesis (e.g. sulphonamides) or nucleic acid synthesis (e.g. quinolones, rifamycins). 
 
 
 
1.4.3.3 Inhibitors of protein synthesis 
There are three general steps in protein synthesis: synthesis of aminoacyl-tRNAs, 
attachment of tRNA molecules to the corresponding amino acids and transport to the 
ribosome, and initiation of ribosomal protein synthesis (reviewed inMcDermott et al. 
2003). Different antibiotics affect different stages of protein synthesis (Table 1.2, Fig. 
1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic representation of the activity of antibiotics that affect protein 
synthesis in the bacterial ribosome. Adapted from: (McDermott et al. 2003). 
 
 
Aminoglycosides, β-lactams, and fluoroquinolones, used in the treatment of 
infections, are described in more detail later in this chapter. 
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Table 1.2 Mechanism of activity of the some of the medically important antibiotics 
Antibiotic a Mechanism of activity Main activity against 
β-lactams: 
Penicillin G 
Methicillin 
Cephalosporins 
Monobactems 
Carbapenems  
Inhibit cell wall synthesis by binding of antibiotic to 
penicillin binding proteins (PBPs) present in the 
cytoplasmic membrane and involved in 
peptidoglycan synthesis. Bactericidal. 
Gram-positive and 
Gram-negative bacteria.  
Glycopeptides: 
Vancomycin 
Teicoplanin 
Inhibit cell wall synthesis by binding to the D-Ala-D-
Ala terminal end of PBPs, preventing them from 
being transported into the cytoplasm to be 
incorporated into the cell wall. Bactericidal. 
Gram-positive bacteria.  
Polymyxins: 
Colistin 
Colistin (polymyxin E) binds to lipopolysaccharides 
and phospholipids in the outer membrane causing 
disruption, leakage and cell death. Bactericidal 
Gram-negative bacteria 
(except Proteus). 
Fluoroquinolones: 
Ciprofloxacin 
Norfloxacin 
Moxifloxacin etc. 
Inhibit DNA synthesis by targeting two essential 
topoisomerases, topoisomerase IV and DNA gyrase. 
Bactericidal. 
Gram-positive and 
Gram-negative bacteria. 
Rifamycins: 
Rifampicin 
Inhibit DNA-dependent RNA polymerase in bacterial 
cells by binding to its beta subunit preventing 
transcription of mRNA and translation to proteins. 
Bactericidal. 
Mycobacterium,  
S. aureus 
Aminoglycosides: 
Gentamicin 
Tobramycin  
Amikacin 
Bind to the 16S rRNA of the 30S ribosomal subunit 
causing misreading of mRNA. Bactericidal. 
Gram-positive and 
Gram-negative bacteria.  
Fusidic acid Interfere with amino acid transfer from aminoacyl-
sRNA. Bacteriostatic or bactericidal. 
Gram-positive bacteria.  
Mupirocin Inhibit ile tRNA synthetase  S. aureus 
Tetracyclines: 
Tetracycline 
Doxycycline 
Prevent the attachment of aminoacyl-tRNA to the 
ribosomal acceptor (A) site. Bacteriostatic. 
Gram-positive and 
Gram-negative bacteria.  
Lincosamides: 
Clindamycin 
Bind to 50S subunit of ribosome inhibiting protein 
synthesis. Bacteriostatic. 
Gram-positive bacteria.  
Chloramphenicol Bind to 50S subunit of ribosome inhibiting protein 
synthesis. Bacteriostatic. 
Gram-positive and 
Gram-negative bacteria.  
Macrolides: 
Erythromycin 
Clarithromycin 
Bind to 50S subunit of ribosome inhibiting 
translocation of peptidyl-tRNA. Bacteriostatic. 
Gram-positive bacteria, 
Mycoplasma, 
Mycobacterium. 
Sulphonamides: b 
Sulphamethoxazole 
Competitive inhibitors of dihydropteroate synthetase 
(DHPS) which catalyses the conversion of PABA 
(para-aminobenzoate) to dihydropteroate in the folate 
synthesis pathway. Bacteriostatic. 
Gram-negative bacteria.  
 
a Some of the more common clinically-important antibiotics. 
b More commonly used in combination. 
1.4.4 β-lactams  
The β-lactam antibiotics include the penicillins, cephalosporins, carbapenems and 
monobactams. After the initial discovery of the naturally occurring antibiotic penicillin, 
semi-synthetic penicillins and cephalosporins (e.g. methicillin, cephalothin, and 
ceftazidime) were prepared by attaching different side chains onto the four-membered 
ring common to all β-lactam antibiotics. Further discoveries of other naturally occurring 
β-lactams led to the development of new cephalosporins (e.g. cefoxitin) and the 
carbapenems. It is the structure of the β-lactam ring, with its side chain, that determines 
the antibacterial spectrum of the antibiotic (Fig.1.3). For penicillin, the β-lactam ring is 
attached to a five-membered thiazolidine ring and a side chain; cephalosporins differ in 
having a six-membered dihydrothiazine ring attached to the β-lactam ring. Addition of a 
methoxyl group has further extended the cephalosporins spectrum of activity. The 
carbapenems differ from penicillins and cephalosporins by a methylene replacement for 
sulphur in the five-membered α-ring structure. Monobactams have little antibacterial 
activity, but modification has produced aztreonam, the only clinically useful 
monobactam. 
 
 
 
 
 
 (a) Penicillin     (b) Ceftazidime 
 
(c) β-lactam ring  
O
N 
(d) Imipenem     (e) Aztreonam 
 
Figure 1.3 Differences in the general structure of the β-lactam antibiotics. R = side 
chains
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1.4.5 Fluoroquinolones 
The first quinolone, nalidixic acid, was introduced in 1962. Fluoridation of the 
quinolone molecule produced norfloxacin, then ciprofloxacin, and then further 
structural alterations produced numerous new quinolones. Fluoroquinolones are broad-
spectrum antibiotics which inhibit DNA synthesis by targeting two related but 
functionally distinct and essential type II topoisomerases, DNA gyrase (a protein 
complex of GyrA2B2 encoded chromosomally by gyrA and gyrB) and topoisomerase IV 
(ParC2E2 encoded by parC and parE). The quinolones stabilise DNA strand breaks 
created by the two topoisomerases by binding to the enzyme-DNA complex, blocking 
DNA replication. In Gram-negative bacteria, DNA gyrase is often the primary target 
whilst topoisomerase IV is the major quinolone target in Gram-positive bacteria.  
 
1.4.6 Aminoglycosides 
 
1.4.6.1 History of the aminoglycosides  
Most of the early aminoglycosides are natural products of the actinomycetes, 
particularly Streptomyces and Micromonospora (Table 1.3) (reviewed by Jana and Deb 
2006). Waksman recovered the first naturally occurring aminoglycoside antibiotic 
(streptomycin)  from Streptomyces griseus in 1943 whilst looking for an antituberculous 
agent (Schatz et al. 1944). More aminoglycosides were isolated from various 
actinomycetes, with gentamicin isolated from Micromonospora purpurea in 1963, 
tobramycin from S. tenebrarius in 1967, and sisomicin from M. inoyensis in 1970. 
Semi-synthetic antibiotics were manufactured by modification of naturally occurring 
compounds in order to extend the antibacterial activity, reduce nephrotoxicity, and 
assist in evading resistance mechanisms. Amikacin was introduced in 1972 as a semi-
synthetic derivative of kanamycin A, followed by dibekacin, netilmicin, and isepamicin, 
all of which were derived from other aminoglycoside antibiotics (Table 1.3). 
 
1.4.6.2 Clinical importance of aminoglycosides 
Aminoglycosides are active against a wide range of aerobic bacteria, (particularly 
Gram-negative bacteria), and are commonly used to treat hospitalised patients. They are 
highly soluble in water, and are more active against bacteria in an alkaline than an 
acidic environment, with poor oral bioavailability. 
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Advantages of the aminoglycosides include low cost, broad spectrum of activity, rapid 
bactericidal action, and, for some organisms, synergy when combined with other 
antibiotics such as β-lactams. However synergy is to some extent dependent on 
antibiotic choices and isolates tested (Giamarellou 1986), and antagonism has even been 
observed (Ervin et al. 1976; Holt et al. 1976; Murillo et al. 1979). Despite this 
inconsistent evidence, aminoglycosides are often used in combination therapy (often 
with a β-lactam) to provide a broader bacterial spectrum, and to prevent the 
development of resistance. 
Table 1.3 Aminoglycosides: source and activity 
Aminoglycoside Source/ organism Year of discovery Comment 
Streptomycin  S. griseus 1943 Active against M. tuberculosis 
Paromomycin S. rimosus var. paromomycinus  1950s Treatment of E. histolytica,  G. lamblia and Leishmania spp. 
Kanamycin A S. kanamyceticus 1957 
Some activity against  
M. tuberculosis. Less active in 
vitro than kanamycin B 
Kanamycin B S. kanamyceticus 1957 
Some activity against  
M. tuberculosis. Less toxic than 
streptomycin 
Spectinomycin S. spectabilis 1961 Treatment of penicillin-resistant  N. gonorrhoeae 
Gentamicin B 
 
Co-produced with gentamicin C  
M. purpurea and echinospora 1963 Similar to kanamycin B 
Gentamicin C 
(C1, C1a, C2) M. purpurea and echinospora 1963 
Active against Enterobacteriaceae 
and P. aeruginosa 
Tobramycin 1967 Enhanced activity against  P. aeruginosa and A. calcoaceticus S. tenebrarius 
M. inyoensis 1970 More potent than gentamicin C More active against P. aeruginosa Sisomicin 
Semi-synthetic derivative of 
kanamycin B 1971 Active against P. aeruginosa Dibekacin 
S. lividus 1971 Respiratory infections, Japan Lividomycin 
Semi-synthetic derivative of 
kanamycin A 1972 
Gentamicin and tobramycin 
resistant organisms Amikacin 
Semi-synthetic derivative of 
kanamycin B 1973 Treatment of MRSA (Japan) Arbekacin 
Netilimicin Semi- synthetic derivative of sisomicin 1975 
More active than gentamicin or 
tobramycin against some Gram-
negatives 
Apramycin S. tenebrarius 1976 
Animal health industry: growth 
promoter and for treatment of E. 
coli and Salmonella infections 
Fortimicin  M. olivoasterospora 
Weak activity against  
P. aeruginosa; less active than 
kanamycin 
1977 
Isepamicin Semi-synthetic derivative of 
gentamicin B (Sch 21420, 1-N HAPA) 
1980 
More active than gentamicin or 
tobramycin against some Gram-
negatives and P. aeruginosa 
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1.4.6.3 Aminoglycoside structure  
The aminoglycosides contain a six membered aminocyclitol ring to which are attached 
amino and hydroxyl groups. Streptomycin differs structurally from other 
aminoglycosides in that its aminocyclitol ring is streptidine, instead of 2-
deoxystreptamine (Fig. 1.4). 
5
NH
NH2
HO
2
1
3
4
OH
NH 26
5
HO
HO
2
1
3
4
OH
NH6
NH2
HN
NH2
HN
HO
5
 
 
 
 
 
 
 
 
2-deoxystreptamine    streptidine 
 
Figure 1.4 Backbone structure of the aminoglycosides (Adapted from Jana and Deb 
2006). 
 
For most clinically useful aminoglycosides, the aminocyclitol ring is 2-
deoxystreptamine joined by glycosidic bonds to two or more amino sugars and further 
division into two major classes is possible based on the position of their glycosidic 
linkages (Spelman et al. 1989). Most of the clinically useful aminoglycosides (Table 
1.3) are 4,6-disubstituted 2-deoxystreptamines (gentamicin, tobramycin, amikacin and 
netilmicin) whilst paramomycin, ribostamycin and neomycin are 4,5-disubstituted. The 
atypical aminocyclitols streptomycin and spectinomycin are classified separately 
(reviewed by Jana and Deb 2006). Spectinomycin, although often considered an 
aminoglycoside, does not contain an amino sugar, and streptomycin contains a 
streptidine molecule as its central molecule (Fig. 1.4).  
Kanamycin is produced by S. kanamyceticus and is composed of three fractions 
(98% A, and the remaining 2% made up of B and C). Gentamicin C, obtained from M. 
purpurea and related species, is also a complex of three different closely related 
aminoglycoside sulphates, 40% C1, 40% C2, and 20% C1a (Table 1.3). Gentamicin B is 
co-produced as a minor component with the gentamicin C complex in fermentations of 
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M. purpurea (Waitz et al. 1972) and its semi-synthetic derivative isepamicin has a 
similar spectrum of activity to amikacin. Specific alterations in molecular structure 
(Table 1.4) are intended to make the newer semi-synthetics less vulnerable to the 
common aminoglycoside-modifying enzymes or to increase their activity.  
 
 
 
  
 
 
 
 
Figure 1.5 Representative structural formulae of the 4,6-disubstituted 2-
deoxystreptamine-containing aminoglycosides. Source: Mingeot-Leclercq et al., (1999). 
 
 
Table 1.4 Variations at the Ra sites for various 2-deoxystreptamine-containing 
antibiotics. Table adapted from Mingeot-Leclercq et al., (1999); Smith et al., (2002). 
 
Aminoglycosides 
 
R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 
Amikacin OH OH OH H NH2 COR’ CH2OH OH H H 
Tobramycin NH2 H OH H NH2 H CH2OH OH H H 
Dibekacin NH2 H H H NH2 H CH2OH OH H H 
Arbekacin NH2 H H H NH2 COR’ CH2OH OH H H 
Gentamicin B OH OH OH H NH2 H H CH3 OH CH3 
Gentamicin C1 NH3 H H CH3 NHCH3 H H CH3 OH CH3 
Gentamicin C1a NH2 H H H NH2 H H CH3 OH CH3 
Gentamicin C2 NH2 H H CH3 NH2 H H CH3 OH CH3 
Gentamicin C2b NH2 H H H NHCH3 H H CH3 OH CH3 
Isepamicin OH OH OH H NH2 COR H CH3 OH CH3 
Kanamycin A OH OH OH H NH2 H CH2OH OH H H 
Sisomicin NH2 H H H NH2 H H CH3 OH CH3 
Netilimicin NH2 H H H NH2 CH2CH3 H CH3 OH CH3 
a R = CHOHCH2NH2 
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1.4.6.4 Mechanism of activity  
Although it is well known that aminoglycosides bind to the bacterial ribosome and 
inhibit protein synthesis, the mechanism of their entry into the bacterial cell is still a 
subject of study (reviewed by Hancock 1981; Taber et al. 1987). The most recent 
evidence is described below. 
 
1.4.6.4.1 
1.4.6.4.2 
Cell entry 
Aminoglycosides are basic, strongly polar, positively-charged cationic compounds, able 
to bind to negatively charged residues (such as lipopolysaccharides and phospholipids) 
in the outer membrane of Gram-negative bacilli. In Gram-positive bacteria, 
phospholipids and teichoic acids are used as the initial binding sites. In a passive, non-
energy dependent process, aminoglycosides diffuse through the outer membrane by a 
process called “self-promoted uptake” and enter the periplasmic space (Hancock and 
Bell 1988). The next phase of transport across the cytoplasmic membrane (so called 
“energy dependent phase I”; EDP-I), varies in duration and rate, depending on the 
external concentration of aminoglycosides. It is thought to depend on the electron 
transport machinery of the cell and is inhibited by divalent cations, high osmotic 
pressure, low pH, and by anaerobiosis (reviewed by Damper and Epstein 1981; 
Hancock 1981; Davis 1987; Taber et al. 1987). Streptococci are resistant to clinically 
achievable concentrations of aminoglycoside, and studies on enterococci have found 
this is to be due to diminished intracellular transport, with the cell wall acting as a 
barrier, as the addition of a cell wall active antibiotic will enhance intracellular uptake 
(Moellering and Weinberg 1971). 
 
Ribosomal activity 
The ribosome is a complex structure comprising three RNA molecules and more than 
fifty proteins. The bacterial ribosome consists of two subunits (50S and 30S), defined 
by their sedimentation rates (Carter et al. 2000; Brodersen et al. 2002; Wilson et al. 
2002) (Fig. 1.6). The 50S subunit comprises two RNA molecules, referred to as the 5S 
and 23S rRNAs, and 33 proteins, while the smaller 30S subunit is made up of a single 
16S rRNA and 20 to 21 proteins.  
During protein synthesis, the 30S subunit plays a crucial role in high fidelity 
translation of genetic information stored in mRNA (reviewed by Vakulenko and 
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Mobashery 2003). Aminoglycosides bind to the 16S rRNA of the 30S subunit causing 
misreading of mRNA. The resulting non-functional proteins compromise the integrity 
of the cytoplasmic membrane (reviewed by Davis 1987; Kotra et al. 2000). 
It is thought that increased permeability of the cytoplasmic membrane allows 
larger quantities of antibiotics to accumulate, resulting in saturation of the ribosomes 
and cell death. The higher the concentration of antibiotic, the more rapid the onset of 
cell death (reviewed by Vakulenko and Mobashery 2003).  
 
 
 
Figure 1.6 Schematic diagram of a ribosome, showing 50S and 30S subunits, decoding 
of information stored in the mRNA, and sequential incorporation of amino acids (aa) 
into a growing polypeptide chain. The site of aminoglycoside-modifying activity is 
marked in red. 
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1.4.7 Mechanisms of resistance 
 
Antibiotic resistance has increased world wide, with resistance to new antibiotics often 
emerging soon after their introduction. Bacterial resistance may be either intrinsic or 
acquired. Some bacteria will not offer a target or adequate access etc., and these are 
termed intrinsically resistant. Acquired mechanisms are more troublesome as by 
definition they are less predictable. The most common acquired mechanisms are 
alteration of the antimicrobial agent (e.g. aminoglycosides, β-lactams), mutation in the 
target site (e.g. aminoglycosides, β-lactams, macrolides, quinolones, rifampicin, 
trimethoprim, tetracycline, mupirocin), antibiotic exclusion (most antibiotics), or 
increased efflux (e.g. tetracycline, macrolides, chloramphenicol, quinolones), and lastly, 
acquisition of an alternate enzyme which is not affected by the antibiotic (e.g. 
sulphonamides, trimethoprim) (Fig. 1.7). 
 
 
 
Figure 1.7 Schematic representation of varying resistance mechanisms, location and the 
antimicrobial agents affected (Adapted from Sundsford et al 2004). 
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1.4.7.1 Intrinsic resistance 
Some bacteria possess natural (intrinsic) resistances, the characteristics of which may be 
useful indicators of the identity of the organism, e.g. cefoxitin resistance in most 
organisms with a chromosomally encoded, inducible AmpC β-lactamase (e.g. 
Enterobacter spp., C. freundii) (Table 1.5). An example of natural resistance is the 
inability of aminoglycosides to penetrate the cell wall of streptococci and enterococci in 
sufficient concentration to be toxic, due to poor transport across the cytoplasmic 
membrane. Enterobacteriaceae are intrinsically resistant to macrolides due to a 
combination of slow transfer across the cell wall and efflux pump extrusion (Kobayashi 
et al. 2001).  
 
Table 1.5 Natural (inherent) resistances of common pathogens 
Organisms Natural resistance to 
All Enterobacteriaceae penicillin G, vancomycin, fusidic acid, macrolides, linezolid, 
mupirocin 
ampicillina, 1st generation cephalosporins A. baumannii 
ampicillin, amoxicillin/clavulanic acid, 1st and 2nd generation 
cephalosporins, cefotaxime, nalidixic acid, trimethoprim 
P. aeruginosa 
Klebsiella spp., C. diversus ampicillin, carbenicillin, ticacillim 
ampicillin, amoxicillin/clavulanic acid, 1st generation 
cephalosporins, cefoxitin 
Enterobacter spp., C. 
freundii 
ampicillin, amoxicillin/clavulanic acid, 1st generation 
cephalosporins, cefuroxime, colistin, nitrofurantoin 
M. morganii 
ampicillin, amoxicillin/clavulanic acid, 1st generation 
cephalosporins, cefuroxime, gentamicin, netilmicin, 
tobramycin, colistin, nitrofurantoin 
Providencia spp. 
P. mirabilis colistin, nitrofurantoin 
P. vulgaris ampicillin, cefuroxime, colistin, nitrofurantoin 
ampicillin, amoxicillin/clavulanic acid, 1st generation 
cephalosporins, cefoxitin, cefuroxime, colistin 
Serratia spp. 
All Gram-positive bacteria aztreonam, colistin, nalidixic acid 
Streptococci trimethoprim, aminoglycosides 
Enterococci penicillin G, carbenicillin, ticarcillin, all cephalosporins, 
aminoglycosides, mupirocin 
a also includes amoxicillin. (Adapted from Livermore et al 2001). 
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1.4.7.2 Decreased antibiotic accumulation by increased efflux 
The first report of antibiotic efflux in bacteria was a tetracycline efflux pump, identified 
in the 1970s. Genes encoding efflux pumps may be on the chromosome or on 
transmissible elements, such as plasmids, and are present in antibiotic-susceptible and 
antibiotic-resistant bacteria. Efflux systems are now recognized as an important 
contributor to antimicrobial resistance, and are more commonly found in Gram-negative 
bacteria, with resistance mediated by increased expression of the efflux pump protein or 
a mutation in the protein increasing the efficiency of export (reviewed by Piddock 
2006). Efflux systems may be specific for one class of drug or capable of 
accommodating a range of chemically distinct antimicrobials (reviewed by Poole 2005 
(a)).  
 
1.4.7.3 Decreased antibiotic accumulation by decreased uptake 
The Gram-negative hydrophobic outer membrane contains a number of channel-
forming proteins (porins), which allow the passage of certain molecules into the 
bacterial cell with varying degrees of selectivity. The outer membrane non-specific 
porin in Pseudomonas spp. (OprF) produces a low level of permeability when compared 
to most other Gram-negative bacteria (e.g. E. coli), significantly reducing access of 
some antibiotics (e.g. β-lactams) to their targets (Yoshimura and Nikaido 1982). 
Acinetobacter spp. are also able to preclude antibiotics more effectively, probably due 
to the small number of small-size porins present in the outer membrane (Sato and Nakae 
1991). A combination of antibiotic-modifying activity, such as a β-lactamase, with an 
alteration to the outer membrane protein (OMP) have resulted in high levels of 
resistance to antibiotics such as the carbapenems that up to recently were highly 
effective (Lee et al. 2007). The OMP is an important point of entry for the antibiotic 
and the combination of β-lactamase activity and reduced permeability results in 
increased resistance.  
 
1.4.7.4 Alteration in the target site 
Alteration of the drug target sites has been implicated in resistance to aminoglycosides, 
β-lactams, macrolides, fluoroquinolones, glycopeptides and sulphonamides (Waterer 
and Wunderink 2001). Mutation of the gene whose product is targeted by the antibiotic 
may increase the level of resistance or expand the spectrum of resistance. 
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Fluoroquinolone resistance may result from mutations in the gyrA, gyrB, parC and parE 
loci (Tenover 2001). Aminoglycoside-producing actinomycetes produce 16S rRNA 
methylases to protect their own 16S rRNAs from intrinsic aminoglycosides, methylating 
ribonucleotide residues at the aminoglycoside binding site on the ribosome (reviewed 
by Cundliffe 1989). Methylation of the bases involved in the binding of the 
aminoglycosides to 16S rRNA by acquisition of a plasmid carrying the genetic 
determinants has been described in Enterobacteriaceae and Pseudomonas.These 
enzymes confer high level resistance to almost all clinically important 4,6-disubstituted 
2-deoxystreptamine aminoglycosides (e.g. amikacin, tobramycin, and gentamicin) 
(Yokoyama et al. 2003; Doi et al. 2004; Galimand et al. 2005).  
 
1.4.7.5 Replacement of target 
The replacement of a target with an alternate pathway is another means of antibiotic 
resistance. For example, in S. aureus, the production of a low-affinity penicillin-binding 
protein (PBP-2a) enables resistance. PBP-2a is the product of mecA, which is part of a 
much larger mobile genetic element, the staphylococcal chromosomal cassette 
(SCCmec), which may also carry other resistance genes. Alteration of the antibiotic 
target to produce a low affinity PBP (PBP5) mediates resistance to ampicillin and 
penicillin particularly in E. faecium. Vancomycin-resistant enterococci (VRE) produce 
altered peptidoglycan pentapeptide precursors that terminate not in the typical D-alanyl-
D-alanine, but in either of D-alanyl-D-lactate (VanA, VanB, VanD) or D-alanyl-D-
serine (VanC, VanE, VanG) which are unaffected by vancomycin (Woodford 2005). 
 
1.4.7.6 Alteration of the antimicrobial agent 
Enzymatic attack of the antibiotic is a common mechanism of resistance, two classic 
examples being the β-lactamases and aminoglycoside-modifying enzymes. β-lactamases 
(Fig 1.9) were initially noted in S. aureus (reviewed by Howe et al. 1996), and are now 
common in Gram-negative bacteria. The genes encoding aminoglycoside-modifying 
enzymes and β-lactamases are found on chromosomes, in gene cassettes and in plasmids 
(see sections 1.8.1 and 1.8.4 for further information on modifying enzymes). 
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1.4.8 Important antibiotic resistance mechanisms 
 
1.4.8.1 β-lactamase resistance (β-lactamases) 
β-lactamases are the most common cause of bacterial resistance to the medically 
important β-lactam antibiotics in Gram-negative bacteria (reviewed by Sundsfjord et al. 
2004). These enzymes may have a broad-host range and varying hydrolysing activity. 
Resistance is usually mediated by β-lactamase enzymes that hydrolyse the β-lactam ring 
before it reaches its target, the PBPs (Fig. 1.8). 
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Penicillin-binding 
protein (PBP) 
Outer membrane 
Periplasm 
Cytoplasmic membrane 
Porin channels
β-lactamases 
 
Figure 1.8 Diagram of the Gram-negative cell envelope with porin channels (dark blue), 
exit channels for efflux (light blue) across which β-lactams must diffuse to reach PBPs 
(dark pink). (Livermore  and Woodford 2006). 
Mechanism of β-lactamase activity 1.4.8.1.1 
 
Figure 1.9 Schematic representation of the 
activity of a serine β-lactamase 
(Ambler classes A, C, and D).  
β-lactamase enzyme is represented in blue.  
Binding: A non-covalent complex is formed 
with the antibiotic.  
Acetylation: The β-lactam ring is attached by 
the free hydroxyl on the side chain of a serine 
residue at the active site of the enzyme, 
leading to a covalent acyl ester.  
Hydrolysis: The ester liberates active enzyme 
and hydrolysed (inactive) β-lactam antibiotic. 
Ambler class B, the metalloenzymes (not 
shown here) use a zinc ion to attack the β-
lactam ring. (Figure adapted from Livermore 
1995). 
 
1.4.8.2 Evolution and classification 
There are now more than 300 β-lactamases, some named for the source organism or 
place of discovery, while others are named for their preferred substrate. The first 
plasmid-mediated β-lactamase isolated from Gram-negative bacteria was TEM-1, 
described in Escherichia coli, and mediates resistance to ampicillin, piperacillin, 
ticarcillin and 1st generation cephalosporins. TEM-2 has a single amino-acid 
substitution that does not significantly alter the substrate profile. SHV-1 was isolated in 
E. coli (plasmid–borne) and in K. pneumoniae (chromosomally encoded). Two 
classifications are in use: the Bush-Jacoby-Medeiros (BJM) classification which 
classifies β-lactamases according to their functional and structural relationship 
(htpp://www.lahey.org/studies/webt.htm) (Bush et al. 1995; reviewed by Jacoby and 
Bush 2005), and the Ambler classification which groups β-lactamases into four major 
classes (A to D) based on genotypic relationships (Ambler 1980) (Table 1.6). 
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Table 1.6 Classification of β-lactamases 
Bush-Jacoby-Medeiros classification 
1 See Ambler class C. Resistant to all except carbapenems; not inhibited by clavulate e.g. AmpC. 
2 See Ambler class A and D. 
2a High-level activity against penicillins; inhibited by clavulate, e.g. Gram-positive penicillinases. 
2b Broad-spectrum β-lactamases inhibited by clavulanic acid; e.g.TEM-1, -2, SHV-1. 
2be ESBLs, inhibited by clavulanate, e.g. TEM-3 to -26, SHV-2 to -6. 
2br Inhibitor-resistant TEMs; e.g. TEM-30 to TEM-36. 
2c Carbenicillin-hydrolysing enzymes, inhibited by clavulanic acid; e.g. PSE-1, -3, -4. 
2d Oxacillinases; inhibited by clavulanic acid; e.g. OXA-1 to –11 (OXA-10 = PSE-2). 
2e Inducible cephalosporinases inhibited by clavulanate, e.g. Proteus vulgaris. 
2f Serine-mediated carbapenemases; e.g. Sme-1, OXA-23 to -27,  OXA-40, OXA-49 
3 See Ambler class B. Metallo-β-lactamases, EDTA inhibited 
3a Hydrolysis: of penicillins>carbapenem>cephalosporins. Requires extra Zn 2+; e.g. IMP, VIM, SPM, GIM 
High carbapenem specificity; some inhibited by high Zn 2+. Do not hydrolyse nitrocefin; e.g CphA. 3b 
High cephalosporinase activity; Legionella gormanii 3c 
Penicillinase from Burkholderia cepacia  4 
Ambler classification 
Active against penicillins, 3rd generation cephalosporins, carbapenems and aztreonam; e.g. TEM, SHV. A 
Metalloenzymes, (carbapenemases) inhibited by EDTA, e.g. VIM, IMP. B 
Cephalosporinases, e.g. AmpC C 
Oxacillinases, inhibited by clavulanate, e.g. OXA. D 
 
1.4.8.2.1 Extended-spectrum β-lactamases 
The arrival of 3rd generation cephalosporins effective against most β-lactamase 
producing bacteria was a major victory in the fight against resistance, but resistance due 
to mutation of the SHV-1 gene was soon evident (Kliebe et al. 1985). Further extended-
spectrum β-lactamases (ESBLs) were discovered, many deriving from TEM-1 and 
TEM-2, and now exceed 200. ESBLs are generally encoded by plasmid-borne genes, 
characteristically hydrolyse oximino-cephalosporins (e.g. ceftriaxone), are inhibited by 
clavulanic acid and sulbactam, and lack activity against cephamycins (cefoxitin) and 
carbapenems. Resistance to 3rd generation cephalosporins in Klebsiella spp. and E. coli 
is usually plasmid-borne and involves multiple resistance determinants, and is often 
indicative of extended-spectrum β-lactamase production (Potz et al. 2006). 
The majority of ESBLs (SHV and TEM derivatives) contain a serine at the 
active site, and belong to Ambler's molecular class A (Bush’s group 2be). The OXA-
type ESBLs (Amber class D, Bush’s group 2d) have more commonly been identified in 
P. aeruginosa and are another growing family of ESBLs. There are several recent 
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excellent reviews describing the origins, epidemiology, detection and clinical 
implications of ESBLs (Bradford 2001; Paterson and Bonomo 2005). Correct detection 
and identification of an ESBL is important for both clinical management and infection 
control. The inhibition of an ESBL by clavulanic acid is useful in most manual and 
automated laboratory detection methods (Fig. 1.10), but variable activity on different 
substrates makes interpretation difficult (Cormican et al. 1996). Simple (non-composite) 
phenotypes are more readily detected by routine laboratory antibiotic susceptibility 
testing but composite phenotypes (e.g. ESBL detection in isolates containing genes 
encoding the chromosomal β-lactamase AmpC) are often difficult to detect.  
 
 
a b
Figure 1.10 Inhibition of ESBL enzyme by clavulanate resulting in (a) typical keyhole 
formation (b) eclipse between Augmentin and aztreonam, typical of ESBL production. 
AMC, Augmentin; ATM, aztreonam; CTZ, ceftazidime; CTX, cefotaxime. 
 
The CTX-Ms are a more recent family of plasmid-mediated ESBLs which were 
initially identified by preferential hydrolysis of cefotaxime. They are better inhibited by 
tazobactam than by sulbactam and clavulanate (reviewed by Giamarellou 2005). This 
class of ESBLs is growing and disseminating rapidly (reviewed by Bonnet 2004) and 
comprise more than 50 enzymes in five subgroups. Kluyvera strains have natural 
chromosomally encoded CTX-M enzymes and similarity between these and acquired 
CTX-M enzymes suggest they may be the progenitors of the CTX-M enzymes now 
prevalent amongst the Enterobacteriaceae and that they were mobilised by insertion 
sequences (reviewed by Poirel et al. 2002; Bonnet 2004). Predominant CTX-M groups 
vary by country; CTX-M-3 and M-15 are predominant in Europe, CTX-M-15 is 
predominant in the UK, emerging after 2001, and we have recently identified CTX-M-
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14 and -15 in ESBL-positive Klebsiella and E. coli at this institution (unpublished). 
Strains with CTX-M that are resistant to ceftazidime as well as cefotaxime have more 
recently been described (Poirel et al. 2001; Poirel et al. 2002). The epidemiology of 
CTX-M enzymes appears to be a result of clonal expansion and plasmid spread and has 
been extensively reviewed relatively recently (Bonnet 2004; Walther-Rasmussen and 
Hoiby 2004). 
 
1.4.8.2.2 Carbapenemases 
Carbapenem antibiotics have the broadest spectra of activity of all the β-lactam 
antibiotics and, since the 1980s, have provided a highly effective treatment option for 
serious infections with P. aeruginosa and ESBL-positive Enterobacteriaceae. They are 
active against most of the common β-lactamase enzymes (Class A, C, AmpC, ESBLs) 
and are active against both Gram-positive and Gram-negative bacteria. The use of 
carbapenems in the treatment of infection has been compromised by the emergence of 
carbapenem-hydrolysing β-lactamases. Carbapenemases that hydrolyse imipenem 
and/or meropenem are classified in either Ambler classes A, B or D (genetic 
differences) or in BJM Groups 2f, 3a or 3b (substrate preference and molecular 
structure). Class A and D carbapenemases are serine carbapenemases, with serine at the 
active site involved in hydrolysis of the β-lactam ring whilst metallo-β-lactamases 
(Ambler class B MBLs) require divalent cations, usually zinc, for activity.  
Class A serine carbapenemases (e.g. SME-1-2, NMC-A, IMI-1, GES-2, KPC-1-
3) include chromosomal, integron and plasmid encoded enzymes and the KPC enzyme 
has been identified in outbreaks in the US. Class A serine-mediated carbapenemases are 
generally more active against imipenem than meropenem, usually active against 
aztreonam but not third generation cephalosporins, and are usually inhibited by 
clavulanic acid (Livermore 1997). 
Ambler Class D serine carbapenemases (oxacillinases) hydrolyse carbapenems 
inefficiently on their own, but when combined with an efflux pump or porin mutation 
produce clinically important levels of resistance. The first of the carbapenem 
hydrolysing OXA-type class D β-lactamases was discovered in an isolate of A. 
baumannii in 1993 and named ARI-1 (Paton R et al. 1993). Imipenem resistance was 
subsequently demonstrated to be transferable (Scaife et al. 1995) and sequence analysis 
of the gene discovered that it encoded an unusual OXA-type enzyme of Ambler 
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molecular class D that was designated OXA-23 (Donald et al. 2000). Since the isolation 
of the first carbapenem-resistant A. baumannii, the incidence of carbapenem 
hydrolysing OXA-type enzymes has continued to increase. At this hospital, 
carbapenem-resistant A baumannii (blaOXA-23) began emerging in about 1998 and 
remained endemic over several years (Chapter 4).  
The class B metalloenzymes (MBLs, e.g. IMP or VIM) hydrolyse most β-
lactams except aztreonam and were first described in P. aeruginosa in 1991 (Watanabe 
et al. 1991), encoded by the gene blaIMP-1. Detection and emergence of MBLs in 
Enterobacteriaceae is further discussed in Chapter 4. blaIMP-4 has been identified in 
Enterobacteriaceae and in Pseudomonas spp. in Australia. This gene, initially identified 
at this institution in 2003, is carried as the first of four cassettes within a class 1 integron 
(blaIMP4-qacG2-aac(6')-Ib (aacA4*)-catB3) (refer to 1.2.8.5.1, Nomenclature) and has 
been implicated in a nosocomial outbreak at the Alfred Hospital, Melbourne, which 
involved 19 clinical isolates from 16 patients (Espedido et al. 2005; Peleg et al. 2005).  
 
1.4.8.2.3 AmpC 
Genes encoding AmpC β-lactamases are commonly found on the chromosomes of 
several members of the family Enterobacteriaceae, particularly Enterobacter spp. 
Providencia spp., C. freundii, M. morganii, S. marcescens (ESCHAPPM isolates) 
(Livermore 1995).  
The “ESCHAPPM” organisms are defined as those which have ampC under 
the control of a series of regulatory genes (ampR, ampG and ampD) which down-
regulate AmpC production, so that under normal situations only a small amount is 
produced. In this group of organisms, exposure to a β-lactam antibiotic will induce 
hyper-production of the enzyme (Fig. 1.11). Inducible expression of AmpC in 
“ESCHAPPM” isolates is regulated by (a) ampR, (coding for an activator of high-level 
ampC expression), (b) ampD (the gene product of which has a negative effect on ampC 
production), and (c) ampG, (necessary for high-level expression of AmpC and thought 
to bind to or activate ampR). Without ampG, AmpR remains inactive. Once the β-
lactam antibiotic is removed, the repressor ampR gene function returns production of β-
lactamase to normal. The isolate may therefore appear susceptible on initial tests but is 
capable of adapting to produce large quantities of β-lactamase enzyme when in contact 
with an appropriate β-lactam antibiotic. Certain mutations may permanently turn off 
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AmpC repression. This phenotype is stable because it has been brought about by genetic 
change, which will be transferred to any progeny and is therefore “stably derepressed”. 
Stably derepressed mutants constitutively overexpress the chromosomal ampC gene and 
have a resistance profile that includes ceftazidime and cefotaxime (Hanson and Sanders 
1999; Livermore and Brown 2001).  
 
 
Figure 1.11 Inducible expression of 
AmpC by exposure of E. cloacae to 
β-lactam antibiotics characterised by 
a flattening of the zone between 
cefotaxime and imipenem. 
 
 
 
Cefoxitin resistance in Enterobacteriaceae is often diagnostic of AmpC 
production (Moritz and Carson 1986; Livermore 1995). The AmpC β-lactamase 
resistance mechanism appears to be increasing in prevalence and may also be present in 
combination with other resistance mechanisms such as ESBLs, or porin down-
regulation, complicating detection and classification. 
Recently, these genes have moved from the chromosome into self-transmissible 
plasmids. Gram-negative bacteria that lack an inducible AmpC enzyme (such as K. 
pneumoniae, E. coli, Salmonella spp. and P. mirabilis) may acquire plasmids resulting 
in a stably derepressed resistance phenotype, since most plasmid-mediated ampC genes 
are expressed constitutively, even in the presence of a complete chromosomal system 
for induction (Jacoby and Tran 1999). Some have DNA and amino acid sequences very 
similar to those of the chromosome-mediated AmpC β-lactamases of Citrobacter 
freundii or Enterobacter aerogenes (reviewed by Hanson and Sanders 1999; Livermore 
and Brown 2001). CMY-2 is the most prevalent of the plasmid-mediated AmpC-type 
enzymes and the most widely distributed geographically (reviewed by Bauernfeind et 
al. 1998). There is no published information on the prevalence of plasmid-borne AmpC 
in Australia. The 2004 AGAR report (Turnidge et al. 2004) identified 3% E. coli and 
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6.6 % K. pneumoniae as cefoxitin-resistant, possibly due to AmpC production, but 
genetic confirmation is not available. 
 
1.4.8.3 Quinolone resistance 
Bacterial resistance to fluoroquinolone has emerged rapidly, usually spontaneously, due 
to mutations in the target topoisomerase genes, decreased expression of outer membrane 
porins, or overexpression of multidrug efflux pumps. High-level resistance is usually 
due to mutations in the topoisomerase genes, reducing binding of the antibiotic to the 
gyrase-DNA complex (Fig. 1.12). Resistance due to decreased drug uptake and efflux is 
usually low-level (reviewed by Drlica and Zhao 1997). 
The plasmid-borne quinolone resistance determinant, qnr, protects DNA gyrase 
from the action of quinolone drugs including the newer fluoroquinolones, and qnr-
bearing strains generate quinolone-resistant mutants at a much higher frequency than 
qnr-free strains. The qnr genes are integron-associated, but not as a cassette, and are 
associated with resistance to several classes of antimicrobials including β-lactams and 
aminoglycosides (reviewed by Hopkins et al. 2005; Paterson 2006). An aminoglycoside 
resistance gene variant (aac(6')-1b-cr) that confers reduced susceptibility to 
ciprofloxacin has recently been described (Robicsek et al. 2006). 
 
  
Figure 1.12 Schematic representation 
of the action of quinolones. Adapted 
from (Drlica and Zhao 1997). 
DNA gyrase and DNA interact to form 
a cleaved complex. Quinolones trap 
the cleaved complex. Gyrase 
mutations (if present) will prevent 
trapping by the quinolones.  
 
The trapped complexes block 
DNA synthesis and cell growth. 
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1.4.8.4 Aminoglycoside resistance: non-enzymatic mechanisms of resistance  
There are three broad mechanisms of aminoglycoside resistance: reduction of the 
intracellular concentration of the antibiotic within the bacterial cell (usually via efflux), 
alteration of the molecular target of the antibiotic, and enzymatic de-activation of the 
aminoglycoside. The most common mechanism of aminoglycoside resistance in 
Enterobacteriaceae is enzymatic de-activation of the antibiotic by aminoglycoside 
modifying enzymes (Fig. 1.13) often encoded by transmissible genes in integrons, 
transposons or plasmids. However, other mechanisms of resistance have been identified 
in Enterobacteriaceae and more often in environmental bacteria such as Pseudomonas 
spp. and are briefly described below (12.8.4.1, 1.2.8.4.2). 
 
1.4.8.4.1 Decreased intracellular concentration 
A decrease in the intracellular concentration of antibiotic due to reduced uptake, 
increased drug efflux, or both, reduces bacterial susceptibility to all aminoglycosides 
and may be due to either intrinsic (natural) or acquired mechanisms (Magnet and 
Blanchard 2005; Jana and Deb 2006).  The stable, resistant phenotype more common in 
P. aeruginosa, particularly in cystic fibrosis patients, and in environmental isolates was 
initially named “impermeability resistance” and thought to be due to reduced uptake of 
the aminoglycoside (reviewed by Poole 2005 (b)). More recent studies have identified 
aminoglycosides as substrates for efflux pumps, such MexXY (also known as AMRAB) 
which confers resistance to multiple aminoglycosides (Aires et al. 1999). 
Aminoglycoside-specific efflux pumps have been detected in A. baumannii, 
Pseudomonas spp., and S. maltophilia, but are rare in the Enterobacteriaceae (reviewed 
by Poole 2004; Poole 2005 (a)). 
Other mechanisms for reduced uptake include respiratory chain mutants or 
strains containing functional mutations in the ATP synthases (Miller et al. 1987; 
reviewed by Taber et al. 1987; Karlowsky et al. 1997), changes in membrane 
components reducing the affinity of the membrane for aminoglycosides (Bryan et al. 
1984), and production of extracellular alginate by mucoid P. aeruginosa (Hatch and 
Schiller 1998). Adaptive resistance has been observed in P. aeruginosa with inducible 
down-regulation of aminoglycoside uptake when grown in the presence of 
aminoglycosides, reverting to susceptible when grown in aminoglycoside-free media 
(Daikos et al. 1990). 
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1.4.8.4.2 Alteration of the molecular target by mutation  
Some aminoglycoside-producing organisms, such as Streptomyces spp., intrinsically 
produce 16S rRNA methylases to protect their own cellular machinery (reviewed by 
Magnet and Blanchard 2005). Methylation of the bases involved in the binding between 
16S rRNA and aminoglycosides (Fig. 1.6) leads to protection of the ribosome from 
aminoglycoside binding, resulting in high-level resistance. However, high-level 
aminoglycoside resistance due to transmissible (plasmid-mediated) 16S rRNA 
methylases has only recently emerged. A 16S rRNA methylase gene, rmtA, was initially 
described in P. aeruginosa (Yokoyama et al. 2003) and two additional genes armA and 
rmtB were more recently detected in E. coli and K. pneumoniae (Galimand et al. 2003; 
Doi et al. 2004). Co-transfer of blaCTX-M or blaSHV with rmtB has been demonstrated in 
E. coli and K. pneumoniae (Yan et al. 2004 (a)). Since its first detection in 
Enterobacteriaceae in 2002, additional 16S rRNA methylases have been identified in 
other members of this group (Yamane et al. 2005). It was thought that widespread use 
of semi-synthetic aminoglycosides, including arbekacin, may have contributed to the 
emergence and selection for this resistance mechanism in Japan. 16S rRNA methylase-
mediated resistance has now also been identified in Enterobacteriaceae in Poland, 
France and Spain. An additional methylase, RmtD, was identified in a P. aeruginosa 
strain isolated in Brazil conferring high-level resistance to most aminoglycosides in 
clinical use. Co-production of a metalloenzyme (SPM-1) provided a substantial role in 
the pan-resistant phenotype and this co-production of SPM-1 and RmtD has since been 
identified as a common phenomenon in hospital isolates of imipenem-resistant P 
aeruginosa in Brazil (Doi et al. 2007 (a); Doi et al. 2007 (b)). 16S rRNA methylases 
have not been detected in Australia to date but dissemination by horizontal transmission 
and by clonal spread, of closely related transferable plasmids containing both 16S rRNA 
methylases and CTX-M have been described overseas and these genes may possibly 
emerge here at some time in the future (Yan et al. 2004 (a); Galimand et al. 2005). 
 
1.4.8.5 Aminoglycoside resistance: aminoglycoside-modifying enzymes 
Enzymatic modification is one of the most important mechanisms of aminoglycoside 
resistance which results in a molecule with decreased binding affinity to the target site 
of the ribosome (reviewed by Vakulenko and Mobashery 2003). Many aminoglycoside-
modifying resistance genes are disseminated on mobile elements, such as plasmids and 
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transposons, within a wide variety of bacterial species (reviewed by Shaw et al. 1993). 
The enzymes modify the antibiotic at its vulnerable hydroxyl and/or amine groups, 
resulting in compounds that cannot interact with the ribosome effectively (Wu et al. 
1997) (Fig. 1.13). Their action upon aminoglycoside antibiotics is due to acetylation, 
adenylation or phosphorylation. They are classified accordingly, as N-acetyltransferases 
(AACs), O-adenyltransferases (ANTs) or O-phosphotransferases (APHs), and the 
encoding genes bear the prefixes aac, ant, and aph respectively (reviewed by Shaw et 
al. 1993). 
 
1.4.8.5.1 Nomenclature of aminoglycoside modifying enzymes 
The nomenclature of aminoglycoside resistance genes has become somewhat 
complicated and confused by the use of two systems. Following the standard 
nomenclature for bacterial genes carried on plasmids, proposed in a review by Novick 
and colleagues in 1976, the genes encoding aminoglycoside acetyltransferases, 
nucleotidyltransferases and phosphotransferases were designated aac, aad, and aph 
respectively (Novick et al. 1976). Division into sub-families is by use of a letter (A, B, 
C etc). In the family of the acetylating enzymes, aacA represents 6'-N-acetyltransferase, 
aacB stands for 2'-N-acetyltransferase and aacC stands for 3-N-acetyltransferase, 
followed by a number to indicate a further subdivision. This classification is based on 
relatedness at the nucleic acid level rather than spectrum of activity or substrate 
preference, but does not encompass all the genes discovered. This has the advantage of 
allowing a simple representation of genetic relatedness, but gives little or no 
information about the all-important phenotype. 
The alternate system, as used by Shaw and colleagues, names the genes according to the 
site of modification on the aminoglycoside, followed by a number (Roman numeral) to 
specify a group of unique resistance phenotypes, then a lowercase letter to distinguish 
between genes with the same phenotypes but different sequences (reviewed by Shaw et 
al. 1993) (Fig. 1.13). For example, aac(6')-Ia is an acetyltransferase gene which 
modifies the aminoglycoside at the 6' site; the Roman numeral (I) groups the enzyme 
into a unique resistance phenotype I, and the letter “a” is used to designate a unique 
protein. According to Novick it is named as aacA1 (thought to be the first discovered 
gene). Since the substrate specificity is largely determined by side chains, Shaw’s 
groups are genetically diverse. Lack of consensus on nomenclature results in apparently 
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conflicting classifications. A clear example is aac(6')Ib (Novick: aacA4), which in fact 
is more genetically similar to the aac(6')-II group than to the other group I genes but has 
been placed in group I due to its amikacin resistant phenotype. Only a single nucleotide 
change is required to alter the phenotype for gentamicin and amikacin resistance, further 
adding to the confusion and resulting in various nomenclatures (aac(6')-Ib, aac(6')-Ib', 
aac(6')-Ib9, aacA4) (Lambert et al. 1994; Mugnier et al. 1998). Thus, while the Novick 
system appropriately defines the two near-identical aacA4 genes as minor genetic 
variants undeserving of separate classification, it fails to distinguish the crucially 
important differences in activity. Searching GenBank (http://www.ncbi.nlm.nih.gov/) 
with aac(6')-Ib and aacA4 (this term including both the non-amikacin-hydrolysing 
variant and the amikacin-hydrolysing variant) detects approximately 100 different 
entries for each nomenclature with some entries naming the gene by both systems. 
For consistency, and to follow the protocol used by the majority of reviewers, the more 
recent nomenclature developed by Shaw and colleagues (reviewed by Shaw et al. 1993) 
will be used with the alternate (genotypic) classification in parentheses where necessary 
or where more commonly used. 
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Figure 1.13 Examples of the sites of acetylation (AAC), adenylation (ANT) and 
phosphorylation (APH) by aminoglycoside-modifying enzymes on one of the more 
susceptible aminoglycosides, kanamycin. Each group of enzymes inactivates specific 
sites. The Roman numerals further group the enzymes by their substrate-specific 
activity. Aminoglycoside abbreviations are as follows (A) amikacin; (Dbk) dibekacin; 
(G) gentamicin; (GmB) gentamicin B; (K) kanamycin A; (I) isepamicin; (N) 
netilimicin; (S) sisomicin; and (T) tobramicin. ( Nomenclature is according to Shaw et 
al. 1993; Source Mingeot-Leclercq et al. 1999). 
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1.4.8.5.2 Activity of phosphorylating enzymes (APH) 
Aminoglycoside phosphotransferases represent a class of enzymes able to 
phosphorylate specific hydroxyl groups in all classes of aminoglycoside antibiotics (Fig. 
1.14). They are most important in Gram-positive bacteria, with APH(3'), the largest 
family, also detected in Gram-negative bacteria (Table 1.7). Most members are unable 
to confer resistance to the medically-important antibiotics gentamicin and tobramycin 
(reviewed by Shaw et al. 1993) however, a hybrid gene aac(6')-Ie-aph(2")-Ia identified 
in staphylococci and enterococci encodes resistance to most aminoglycosides (reviewed 
by Jana and Deb 2006). 
  
Figure 1.14 Phosphorylation of kanamycin by APH(3')s. Arrow (red) indicates site of 
modification. (Source: Vakulenko et al. 2003). 
 
Table 1.7 Substrate profiles of APH(3') phosphotransferases 
(Shaw et al. 1993; Vakulenko et al. 2003). 
APH(3')- Location Species association Substrates a 
I Tn903 
Transposon, 
Plasmids 
Enterobacteriaceae, Vibrio, 
Campylobacter, Pasteurella, 
Acinetobacter 
gentamicin B, kanamycin, neomycin, 
paramomycin,  
II Tn5 
Chromosomal  
Uncommon in Gram-negative 
bacteria 
(amikacin), gentamicin B, kanamycin, 
neomycin, paromomycin,  
III Plasmid S. aureus, Enterococcus spp., 
Campylobacter 
(amikacin), gentamicin B , (isepamicin), 
kanamycin, neomycin, paromomycin,  
IV Chromosomal B. circulans kanamycin, neomycin, paromomycin 
V Chromosomal Streptomyces,  kanamycin, neomycin, paromomycin 
Micromonospora spp. 
VI Plasmid Uncommon in Gram-negative 
bacteria 
amikacin, gentamicin B, isepamicin, 
kanamycin, neomycin, paromomycin,  
Campylobacter VII Plasmid (amikacin), kanamycin, neomycin  
a Parentheses indicate in vitro modification only. 
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1.4.8.5.3 Activity of acetyltransferases (AAC) 
The largest family of aminoglycoside-modifying enzymes is the acetyltransferases 
(AACs), which comprise four classes of enzymes: AAC(1), AAC(3), AAC(2'), and 
AAC(6'). This family of enzymes utilizes acetyl coenzyme A as the donor of the acetyl 
group to modify aminoglycosides at positions 1 or 3 of the 2-deoxystreptamine ring and 
positions 2' or 6' of the 6-aminohexose ring (Fig. 1.13) and its members are therefore 
classified accordingly. The AAC(6') and AAC(3) groups are more commonly 
encountered in clinical isolates and confer resistance to many clinically important 
aminoglycosides (Table 1.8). 
 
 
Figure 1.15 Acetylation of kanamycin by AAC(6')s. Arrow (red) indicates site of 
modification. (Source: Vakulenko et al. 2003). 
 
AAC(1) enzymes have been identified in E. coli but do not produce resistance to the 
commonly encountered medically important aminoglycosides such as gentamicin, 
tobramycin and amikacin (Lovering et al. 1987; reviewed by Magnet and Blanchard 
2005) (Table 1.8).  
 
Members of the AAC(2') subclass have been found chromosomally encoded in 
Providencia spp. and enzyme activity has been shown to increase after exposure to 
aminoglycosides (Swiatlo and Kocka 1987). Expression of AAC(2') occurs at low levels 
in wild-type strains which are aminoglycoside susceptible with mutant colonies 
emerging after growth on gentamicin-containing media (Rather et al. 1993).  
 
Aminoglycoside-3-acetyltransferases (AAC(3)s) are widely distributed. This is 
the second largest group of acetyltransferases and this mechanism the second most 
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common type of aminoglycoside acetyltransferase-mediated resistance after AAC(6') 
(reviewed by Vakulenko and Mobashery 2003). The known AAC(3)s are classified into 
several groups based on phenotype (reviewed by Shaw et al. 1993). More recently a 
reclassification of the group, based on their protein similarity, has been proposed 
(Levings et al. 2005). For those genes located in gene cassettes (aac(3)-Ia, -Ib, -Ic), 
encoding related proteins of 154–158 amino acids, Levings has proposed an alternate 
nomenclature adding the letter A into the name (e.g. aacCA2). The remaining aac(3) 
genes are not found in gene cassettes, and encode longer proteins of 261–300 amino 
acids, and appear unrelated to the AAC(3)-I group. 
The AAC(3)-I enzymes produce a narrow spectrum of resistance which includes 
gentamicin, sisomicin and fortimicin, but not tobramycin, amikacin or kanamycin, and 
are exclusively found as gene cassettes within integrons, generally located in 
transposons or plasmids. 
The AAC(3)-II subclasses are commonly seen in clinically significant Gram-
negative bacteria, particularly in E. coli (Vanhoof et al. 1999; Over et al. 2001), and are 
not found in gene cassettes. The aac(3)-IIc gene shows 97% identity and the aac(3)-IIb 
gene shows 72% identity with aac(3)-IIa. Co-transfer of this class with an ESBL 
phenotype on a conjugative plasmid has been described (Naiemi et al. 2005). This 
group was also designated AAC(3)-V, but as the genes were found to be identical to 
those in AAC(3)-II it has been renamed (Novick gene nomenclature aacC2, aacC3, 
aacC5). 
AAC(3)-III and -IV have been isolated from P. aeruginosa, and AAC(3)-VI 
from E. cloacae (Shaw et al. 1993), but are regarded as rare in Enterobacteriaceae 
(Novick gene nomenclature aacC3 and aacC4 respectively). 
 
Aminoglycoside-6'-acetyltransferases (AAC(6') are broad-spectrum enzymes 
which acetylate aminoglycosides (Fig. 1.15) with free primary 6' amino groups, capable 
of modifying most of the clinically important aminoglycosides (Table 1.8). They have 
been identified in various Gram-negative bacteria including Enterobacteriaceae, 
Acinetobacter spp. and P. aeruginosa (reviewed by Shaw et al. 1993), and may be 
further divided into three sub-families at the level of protein sequence relatedness. 
aac(6')-Ib is commonly identified in Gram-negative bacteria, located in a gene cassette, 
often in association with the ESBL phenotype on mobile plasmids (Levesque et al. 
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1995; Sallen et al. 1995; Turton et al. 2005; Lavollay et al. 2006). Some aac(6')-I genes 
are located on the chromosome and may be species-specific (e.g. aac(6')-Ic, S. 
marcescens). aac(6')-Ie is part of the fused gene aac(6')-Ie-aph(2'')-Ia which codes for 
resistance to most aminoglycosides in staphylococci and enterococci (reviewed by 
Shaw et al. 1993), whilst all E. faecium strains have a chromosomally-encoded gene 
aac(6')-Ii that confers resistance to tobramycin, sisomicin, netilmicin and kanamycin 
(Costa et al. 1993). 
aac(6')-IIa and aac(6')-IIb were initially detected in P. aeruginosa, and their 
products mediate resistance to gentamicin, tobramycin, and netilmicin but not amikacin 
or isepamicin. AAC(6')-IIa has 82% protein similarity to AAC(6')-Ib (encoded by 
aac(6')-Ib [Shaw]/aacA4 [Novick]), which has a different substrate profile (resistant to 
amikacin but not gentamicin) suggestive of common ancestry (Shaw et al. 1989). Since 
its initial detection there have been reports of aac(6')-IIc in class 1 integrons in E. 
cloacae thought to be chromosomally located (Galani et al. 2005), and on a mobile 
plasmid in Salmonella (Gassama-Sow et al. 2004).  
 
Table 1.8 Substrate profiles of the more common aminoglycoside acetyltransferases 
against clinically relevant antibiotics useful in treating infections with Gram-negative 
bacteria. (Adapted from Shaw et al.1993; Vakulenko and Mobashery 2003). 
Location Species association Substrates a  
AAC (6')    
I Gene cassette, 
Transposon, 
Chromosome 
Enterobacteriaceae, 
Pseudomonas, Acinetobacter 
tobramycin, amikacin, netilimicin, 
dibekacin, sisomicin, kanamycin, 
(isepamicin) 
    
Pseudomonas,  
Enterobacteriaceae 
tobramycin, gentamicin, netilimicin, 
dibekacin, sisomicin, kanamycin 
II 
 
 
Gene cassette, 
Chromosome 
    
AAC(3)    
Gene cassette  Enterobacteriaceae, 
Acinetobacter, Pseudomonas  
gentamicin, sisomicin, fortimicin 1a, Ib 
    
Plasmid Enterobacteriaceae (common 
in E. coli), Acinetobacter, 
Pseudomonas 
tobramycin, gentamicin, netilimicin, 
dibekacin, sisomicin 
IIa, IIb, IIc 
    
IIIa, IIIb, IIIc Plasmid Pseudomonas,  Enterobacter tobramycin, gentamicin,  dibekacin, 
sisomicin, kanamycin, neomycin, 
paramomycin, lividomycin  
    
IV Plasmid Uncommon (Pseudomonas, 
Enterobacteriaceae)  
tobramycin, gentamicin, netilimicin, 
dibekacin, sisomicin 
    
VI Plasmid Uncommon (Enterobacter) tobramycin, gentamicin, netilimicin, 
sisomicin (kanamycin) 
 
    
AAC(1) Not known E. coli paromomycin, lividomycin, 
ribostamycin, apramycin 
    
    
AAC(2')-1a Chromosome All Providencia stuartii tobramycin, gentamicin, netilimicin, 
dibekacin, neomycin 
    
a Parentheses indicates in vitro resistance, but not clinical resistance. 
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1.4.8.5.4 Activity of adenyltransferases (ANT) 
The aminoglycoside nucleotidyltransferases comprise 5 classes. ANT(2''), ANT(3''), 
ANT(4'), ANT(6) and ANT(9) and modify aminoglycoside antibiotics by transferring 
AMP to their hydroxyl group at positions 2'', 3'', 4', 6, and 9 respectively (reviewed by 
Vakulenko and Mobashery 2003) (Fig. 1.16).  
 
 
Figure 1.16 Adenylation of kanamycin A by ANT(2"). Arrow (red) indicates site of 
modification. (Source: Vakulenko and Mobashery 2003). 
 
 
This is the smallest class of aminoglycoside-inactivating enzymes, with only 10 
identified to date. The genes encoding ANT(2'') and ANT(3'') have been identified in 
Gram-negative bacteria, whilst the genes encoding ANT(4'), ANT(6) and ANT(9) are 
often found in Gram-positive organisms (reviewed by Jana and Deb 2006). The 
enzymes ANT(2'') and ANT(4') both confer resistance to the clinically important 
antibiotics gentamicin, tobramycin and dibekacin but not amikacin. The gene for 
ANT(2'')-Ia is more commonly named aadB (rather than ant(2")-Ia) and is frequently 
encountered in Enterobacteriaceae (Table 1.9). 
Table 1.9 Substrate profiles of aminoglycoside nucleotidyltransferases 
(Table adapted from Shaw et al. 1993; Vakulenko et al. 2003) 
ANT Location Species association Substrates 
 
ANT(2'')-I 
 
Gene cassette 
 
Widespread 
Enterobacteriaceae 
 
tobramycin, gentamicin, dibekacin, 
sisomicin, kanamycin 
 
ANT(3'')-I 
 
Gene cassette 
 
Widespread 
Enterobacteriaceae,  
P. aeruginosa, Vibrio spp 
 
streptomycin, spectinomycin 
 
ANT(3'')-II 
 
Gene cassette 
 
Frequent in Gram-
negative bacteria 
 
streptomycin, spectinomycin 
ANT(4')-Ia Plasmid Gram-positive bacteria tobramycin, amikacin, dibekacin, 
kanamycin, isepamicin 
Pseudomonas, 
Enterobacteriaceae 
ANT(4')-IIa Plasmid, 
Transposon 
tobramycin, amikacin, kanamycin, 
isepamicin 
Gram-positive bacteria streptomycin ANT(6)-I Plasmid 
ANT(9)-I Transposon S. aureus spectinomycin 
 
 
 
1.4.8.6 Trimethoprim-sulphamethoxazole resistance (cotrimoxazole) 
The major cause of trimethoprim resistance in Gram-negative bacteria is plasmid-borne 
dihydrofolate reductase (dfr) genes, which are commonly found as gene cassettes in 
class 1 integrons (White et al. 2000). The sulfamethoxazole resistance gene sul1 is also 
commonly associated with type 1 integrons, not as a gene cassette, but located in the 3' 
conserved segment (3'-CS) of the integron downstream from the cassette(s) (Hall and 
Collis 1998). Resistance to sulphamethoxazole in the absence of a detectable sul gene 
has been described (Grape et al. 2005; Blahna et al. 2006). The sulfamethoxazole 
resistance genes sul2 and sul3 are often found on other common horizontally 
transferable elements such as transposons and plasmids and sul2 was found to be more 
common than sul1 in a recent large European study (Blahna et al. 2006). 
 
 44
1.4.9 Mechanisms of transfer of resistance 
 
1.4.9.1 Conjugative transfer of DNA via plasmids  
Plasmids are genetic elements that replicate independently of the chromosome and play 
a crucial role in the sharing of genetic information. Most are circular, double-stranded 
DNA molecules, diverse in size and copy number, and carry additional genetic 
information such as resistance determinants.  
Plasmids able to mediate their own transfer from one cell to another are called 
conjugative plasmids. Conjugation involves the unidirectional transfer of bacterial 
genetic material from donor to recipient in environments where cell contact is frequent 
including the human gut. It is usually associated with a round of plasmid replication, 
and comes at some metabolic cost (Balis et al. 1996). 
 
 
 
Figure 1.17 Transfer of DNA via conjugative plasmid. (Murray et al. 1998). 
 
Conjugative transfer in Gram-negative bacteria starts with the synthesis of an 
extracellular pilus, which establishes cell-to-cell contact. In the second stage, a single 
strand nick at the origin of transfer enables the transfer of one strand to the recipient. A 
complement to the transferred strand is synthesised in the recipient, followed by 
separation of the donor and recipient cells (Fig 1.17). Transmissible plasmids have also 
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been reported in many Gram-positive bacteria including enterococcus and 
staphylococcus but there are essential differences in the mechanisms used to establish 
cell to cell contact. They do not appear to use pili as an initiator of conjugation, instead 
transfer appears to be by aggregation of bacterial cells mediated by cell surface 
structures (reviewed by Grohmann et al. 2003).  
As well as conjugative transfer, plasmids can be transferred by transduction 
(mediated by bacteriophage) and by transformation (natural uptake of plasmid DNA by 
a bacterial cell). 
 
1.4.9.2 Integrons 
Integrons are potentially mobile genetic elements that are capable of acquiring and 
expressing genes in the form of gene cassettes. There are several classes of integrons, 
each with a distinct integron-specific integrase (IntI). Class 1 integrons are the most 
common class found in clinical isolates, are widespread amongst Enterobacteriaceae 
and are strongly associated with multi-drug resistance, both in hospital isolates and in 
the community (Leverstein-van Hall et al. 2003). PCR using primers situated in the 
highly conserved 5'- and 3'-conserved segment (CS) regions characteristic of these 
structures can be used to amplify gene cassettes orientated in tandem array between the 
5'-CS with its promoter sequence, and the 3'-CS (Fig 1.18) which usually contains a 
gene conferring resistance to sulphamethoxazole (sul1) (Hall and Collis 1995; White et 
al. 2000). 
 
 
 
Figure 1.18 Schematic representation of part of the basic class 1 integron structure 
consisting of the 5'-CS containing intI1, attI1, promoter Pc, P2, and the 3'-CS 
containing qacEΔ1, sul1, and orf5. Adapted from (Levesque et al. 1995). 
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Gene cassettes are discrete mobile genetic elements that normally contain one gene and 
a short sequence called a 59-base element (59-be) that acts as a recombination site. 
Gene cassettes may exist as free, circular, non-replicating DNA molecules but are 
normally found as linear sequences, usually within an integron (Hall et al. 1991; Collis 
and Hall 1992). The genes carried by gene cassettes usually lack promoters and are 
expressed from a promoter (Pc) in the integron. A second promoter P2 has been found in 
a small number of class 1 integrons and is also responsible for expression of the 
resistance genes (Collis and Hall 1995). 
Insertion of a free circular cassette into an integron involves site-specific 
recombination between the attI site and a 59-be located at the 3' end of the gene. 59-be 
are variable in length (57-141 bp) and their similarities are primarily restricted to their 
boundaries, which correspond to the inverse core site (RYYYAAC) and the core site 
(GTTRRRY), where R represents purine and Y represents pyrimidine (Fig. 1.18). 
IntI can also catalyse the excision of cassettes from integrons and as a result can 
change the number and order of cassettes within an integron (reviewed by Hall and 
Collis 1995) (Fig. 1.19). Due to its proximity to Pc, a resistance gene located in the first 
cassette will confer a higher level of resistance than when located further downstream. 
Shuffling or excision of cassettes may thus allow selection for increased resistance to a 
particular antibiotic (Collis and Hall 1995). 
 
Figure 1.19 Schematic 
representation of a class 1 
integron and the 
incorporation of a gene 
cassette. The gene cassette 
is incorporated into the 
integron structure by the 
site-specific recombinase 
IntI1. Adapted from 
(Bennett 1999). 
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The 5'-CS of a class 1 integron has a 25-bp sequence (IRi) at its outer end and at 
the opposite end of the integron is an inverted repeat IRt. Most class 1 integrons have 
lost all or part of their tni transposition region resulting in transposon derivatives that 
are defective in self-transposition (Partridge et al. 2002). Class 1 integrons may reside 
on the bacterial chromosome but are commonly mobile because they are incorporated 
into a plasmid or a transposon (such as Tn21). 
 
1.4.9.3 Transposons 
Transposons are recognized as an important mechanism of dissemination of antibiotic 
resistance genes. They are discrete DNA sequences able to insert more or less 
indiscriminately into other DNA sequences by recombination, which is mediated by a 
transposase encoded within the transposon. Most transposons reside on plasmids, and 
are capable of transposition between plasmid and chromosome transferring any 
antibiotic resistance genes within them (reviewed by Davies and Smith 1978; Liebert et 
al. 1999). They differ from plasmids in that, although some form a circularized 
intermediate, they do not replicate independently and are usually incorporated into the 
bacterial chromosome (Mullany et al. 2002).  
Transposons were initially named for the antibiotic resistance that they 
encoded: for example TnA encoded ampicillin resistance. However, as more 
transposons were identified, it soon became evident this system would not work and 
numbers were assigned, with Tn1 named as the first discovered transposon. Tn21 and 
its relatives form a subgroup of the Tn3 family and are associated with the 
dissemination of antibiotic resistance determinants in Enterobacteriaceae (Hall and 
Collis 1998). Transposons in this subgroup often carry an integron and a mercury 
resistance (mer) operon (reviewed by Liebert et al. 1999) (Fig. 1.20) and also contain a 
transposase gene (tnpA), a resolvase gene (tnpR), the putative transposition regulator 
(tnpM) and the resolution site (res). The class 1 integron (In2) within Tn21 carries the 
aadA1 gene cassette that confers aminoglycoside resistance (Fig. 1.20). 
Insertion sequence (IS) are simpler mobile elements containing only those genes 
required for transposition. 
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Figure 1.20 A schematic diagram representative of Tn21 found in the plasmid NR1. 
Arrows indicate the direction of transcription of the various genes; the solid ellipse 
represents the aadA1 59-base element. Adapted from (Liebert et al. 1999; DiPersio et 
al. 2005). 
 
Composite transposons consist of two insertion sequences (IS) flanking 
intervening DNA that often includes a genetic determinant for antibiotic resistance, and 
this structure moves as a unit. (reviewed by Salyers and Amabile-Cuevas 1997). For 
example, the aminoglycoside methylase gene armA, encoding multiple aminoglycoside 
resistance, has been identified as part of the composite transposon Tn1548 (Galimand et 
al. 2005). 
Conjugative transposons are defined as discrete DNA elements, which can 
transfer from donor to recipient by conjugation. They differ from plasmids in that 
although they have a covalently closed circular intermediate, they cannot replicate 
independently. Conjugative transposons were initially discovered in Gram-positive 
cocci in the 1970s, in E. faecalis (Tn916) and S. pneumoniae (Tn5253). Since then, a 
number of other conjugative transposons in Gram-positive bacteria have been described 
(for review see Salyers et al. 1995). Conjugative transposons (including Tn916) have 
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also been identified in Gram-negative bacteria (e.g. Kingella, Neisseria, Bacteroides 
spp.). 
 
1.4.9.4 Transduction (Bacteriophages) 
Bacteriophages are extrachromosomal genetic elements (DNA or RNA) termed 
bacterial viruses due to their ability to infect bacterial cells and to transfer 
independently. Phages are ubiquitous and can be found, for example, in soil, the 
intestine of animals, and seawater. As they are not mobile, random encounters with the 
host are necessary for infection. To enter the host cell, the bacteriophage must attach to 
specific receptors on the surface of the bacteria and may therefore only infect bacteria 
carrying these receptors. Once inside the cell they may integrate into the host genome 
without killing the host or replicate in large numbers causing the cell to lyse. When 
exiting the host genome, pieces of host DNA that may contain resistance determinants 
may also be transferred by chance, along with the bacteriophage (reviewed by 
McDermott et al. 2003). 
 
1.4.9.5 Transformation 
Transformation is the process by which naturally competent bacteria pick up DNA from 
their environment. Active uptake and integration is termed natural transformation and 
makes a large contribution to horizontal transmission of genetic material in prokaryotes 
(reviewed by Dubnau 1999; de Vries and Wackernagel 2002; Sikorski et al. 2002). 
Some bacteria preferentially take up DNA of their own species, whilst others, such as 
Acinetobacter spp., have no preference, and will take up foreign DNA in similar 
proportions (reviewed by Dubnau 1999).  
 
1.4.10 Infection control 
Surveillance for resistant bacteria is an important aspect of infection control 
management, firstly to identify patients requiring contact isolation but also to monitor 
the prevalence of antibiotic-resistant organisms, to identify problem pathogens and to 
evaluate intervention strategies (reviewed by Vandenbroucke-Grauls and Schultsz 2002; 
Peterson 2005).  
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1.4.10.1 Surveillance in infection control: national and local. 
Active surveillance is now an important part of routine microbiological testing but is 
typically limited to select problem pathogens and patients most at risk. There is some 
debate over the cost effectiveness of infection control screening programs, particularly 
for low prevalence pathogens, but a low prevalence of MRSA in northern Europe is 
attributed to aggressive infection control measures involving screening and contact 
isolation (Fang and Hedin 2003). The cost of screening means that it is often limited to 
patient groups at high risk, such as those in the intensive care unit; however, large well 
co-ordinated surveys are necessary to predict trends in resistance development and to 
detect all potential carriers (Lee et al. 2005). 
Prevention and control of MRSA and VRE has received considerable attention 
and a variety of phenotypic and genotypic methods have been developed and published. 
Resistance screening of Enterobacteriaceae is not performed at this institution but 
overseas surveys have highlighted the increasing problem of resistance in 
Enterobacteriaceae and outbreaks due to ESBL-containing organisms (reviewed by 
Giamarellou 2005; Paterson 2006). 
 
1.4.10.2 Justification for rapid detection  
Nosocomial infection is also associated with increased hospital costs as well as poor 
clinical outcome (Pittet et al. 1994). Inadequate or delayed therapy for critically ill 
patients with sepsis and ventilator-associated pneumonia is associated with a higher 
mortality rate, whilst early initiation of correct antimicrobial therapy reduces the 
mortality rate (Kollef 1997; Luna et al. 1997; Rello et al. 1997; Ibrahim et al. 2000). 
Colonisation of patients with multi-resistant organisms precedes the 
development of clinically significant infections (Donskey 2006). Early detection of 
colonisation allows early appropriate clinical decision making and infection control 
intervention as dissemination of antibiotic resistance determinants occurs more 
commonly among immobilized, intubated, critically ill patients (reviewed by Sundsfjord 
et al. 2004). The arrival and dissemination of bacteria carrying new resistances will 
remain unnoticed unless patients are screened for colonisation, and outbreaks may not 
be detected using phenotypic data on clinically significant isolates alone (Thomas et al. 
2005). 
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1.4.10.3 Laboratory screening for resistance 
Critical and timely intervention for serious infection requires rapid and accurate 
detection of the pathogen and any resistance but the conventional methods used in 
laboratories remains the traditional slow culture–based assay (reviewed by Yang and 
Rothman 2004). A typical example is in the diagnosis of “sepsis” (blood stream 
infection) where patients presenting with clinical symptoms may not be treated with the 
appropriate antibiotic therapy due to the necessary delay for the growth of the isolate, 
and for identification and susceptibility tests. It is from the limited available information 
such as Gram stain result that the clinician must make decisions on appropriate 
antibiotic therapy. All susceptibility testing requires inocula of a pure growth of the 
isolate. If there is insufficient growth or the potential for mixed inocula, subculture is 
necessary, taking a further 24 h to result. Inadequate microbiological support of 
infection control measures may result in unnecessary isolation of some patients, and the 
failure to recognise the need to isolate others (reviewed by Diekema et al. 2004). 
 
1.4.10.4 Antimicrobial stewardship 
Antimicrobial stewardship is the implementation of specific restrictions on antibiotic 
use within a hospital as a strategy to overcome emergence of resistance. Implementation 
of antimicrobial stewardship programs in American hospitals recommended strategies 
such as antimicrobial substitution to reduce costs, changing from intravenous to oral 
antibiotics, approval by an infection control practitioner for certain classes of 
antibiotics, and limited days of use. A recent review by MacDougall et al. emphasised 
the importance of the microbiology laboratory in antimicrobial stewardship, not only in 
providing resistance data but also in reducing inappropriate antibiotic use by only 
releasing antibiotics relevant to the site and nature of the isolate identified. Outbreaks 
may be reduced if the antimicrobials known to be associated with resistance are 
controlled (Rahal et al. 1998), however the concept of using an alternate antibiotic may 
not be a long-term solution. Both MacDougall and Giamarellou described several 
studies, all of which succeed in reducing resistance to the antibiotic of concern, but also 
noted emerging resistance to the alternate antibiotic used (reviewed by Giamarellou 
2005; MacDougall and Polk 2005)  
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1.4.11
1.4.12
 Phenotypic testing 
Currently, published standards exist for media preparation, incubation parameters and 
the interpretation of results for disc diffusion, broth dilution, and agar dilution 
susceptibility testing, provided by the Clinical and Laboratory Standards Institute 
(CLSI), formally NCCLS.(CLSI 2005). Within the CLSI guidelines, the described 
protocols available vary in cost, expertise, labor input and equipment requirements. The 
use of Mueller Hinton agar plates seeded with a bacterial culture diluted to a 0.5 
McFarland inocula density, and the application of standardised concentration antibiotic 
discs is a rapid and inexpensive method used in this and other laboratories. However, 
the method requires measurement of zone sizes and comparison to CLSI tables to 
interpret phenotypes as susceptible or resistant, with no actual minimum inhibitory 
concentration (MIC) result derived. Alternative methods using dilutions of antibiotics 
incorporated into agar plates (e.g. replicator systems) or in broth provide the actual MIC 
of the antibiotic necessary to inhibit growth of the isolate but require accurate addition 
of antibiotics to the media which may have a shorter shelf life than when incorporated 
into discs for disc testing. Where CLSI interpretation guidelines do not provide zone 
size interpretation, an Etest using a commercially manufactured strip (AB BIODISK, 
Solna, Sweden) which is impregnated with dilutions of antibiotic will provide an MIC 
(e.g. penicillin susceptibility for Streptococcus pneumoniae). There are a number of 
automated systems available such as the BD Phoenix and Vitek systems (see Chapter 2 
2.2.10.2), which provide results within 24 h. An “expert” system makes decisions 
including isolate identification according to different pre-determined rules. If an isolate 
identification is incorrect, it will make incorrect adjustment of results. These systems 
have difficulty with detecting composite phenotypes, such as ESBL-AmpC, and may 
miscall new resistance mechanisms such as blaIMP-4 (Espedido et al. 2007).  
Infection control screening using phenotypic methods, due to the nature of the 
specimens usually tested (perineal swabs), is laborious and time consuming, results take 
up to 72 h, and only selected patients and selected pathogens are screened for (Chapter 
4). 
 
 Rapid methods 
Rapid detection methods, in particular conventional polymerase chain reaction (PCR) 
and real-time PCR have increasingly become accepted as standard methods for the 
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detection of a variety of bacteria and phenotypes, improving time-to-result as well as 
sensitivity and specificity. PCR can be an addition to, or a replacement for, routine 
culture; for example, the advent of real-time PCR has allowed earlier identification and 
quantitation of some of the more fastidious and slow growing bacterial pathogens (e.g. 
Legionella spp) (Yang and Rothman 2004). Results available to the clinician more 
quickly allow more specific and timely use of antibiotics, reducing improper use of 
antibiotics and selection for resistance. PCR is particularly useful where rapid 
identification of medically important resistance mechanisms is required (e.g. in blood 
stream infections) to make accuarte antibiotic choices. Rapid methods such as PCR are 
also useful for the confirmation of phenotypic results (e.g. mecA in MRSA, van in VRE) 
where phenotypic methods may only be suggestive of the presence of a resistance gene. 
PCR may also be used to directly test patient samples (e.g. rectal swabs, nasal swabs) as 
an early predictor of infection (prior colonisation) (reviewed by Cockerill 1999; 
Diekema et al. 2004) } Rapid methods allowing appropriate antibiotic therapy choices 
will potentially reduce both hospital and patient associated costs (Van Eldere 2005). 
 
1.4.12.1 Conventional PCR 
The polymerase chain reaction (PCR) was initially developed in 1985 and is the most 
commonly used method to detect resistance genes. It relies on prior knowledge of target 
DNA, or at least part of the sequence, and requires the design of specific primers that 
will hybridize to the target DNA. Conventional PCR will provide a same day result but 
requires laborious, post-amplification processing (gel electrophoresis) to be performed 
at the end of the amplification process. Issues of cross-contamination and reduced 
sensitivity have been somewhat overcome by the emergence of real-time PCR, which 
enables the product to be detected in “real-time”, that is, as it amplifies, and is less 
operator dependent. 
 
1.4.12.2 Real-time PCR 
“Real-time” PCR (Chapter 3, SAM-PCR) based on fluorescence detection, has been 
developed as a cost-effective, user friendly format requiring less operator input, for use 
in surveillance screening as well as for use in detection of specific resistance genes and 
confirmation of ambiguous results (reviewed by Sundsfjord et al. 2004). Real-time 
fluorescence technology using SYBR Green is less expensive than probe technology, 
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but binds non-specifically to double-stranded DNA generated during amplification. 
Equipment that uses a melt curve analysis on the resulting amplicon permits detection 
of different amplification products, resulting in increased specificity. Probe-based real-
time PCR is sensitive and specific with available variations in probe format including 5' 
nuclease probes (TaqMan probes), molecular beacons and FRET hybridisation probes. 
These probe technologies all rely on fluorescence resonance energy transfer (FRET), 
which transfers light energy between two adjacent dye molecules. As the distance 
between the two adjacent dye molecules increases, FRET decreases allowing 
fluorescence detection. For TaqMan or molecular beacons, the two dye molecules 
(fluorophor and quencher) are attached to a single probe. TaqMan probes that bind to a 
complementary strand of DNA are cleaved by the nuclease activity of Taq polymerase 
separating the fluorescent dye from the quenching dye. Molecular beacons form a 
hairpin structure in solution bringing the fluorophor and quencher dyes into close 
proximity quenching fluorescence. In the presence of target sequence, the probe 
anneals, increasing the distance between between the two adjacent dye molecules, 
allowing fluorescence output to increase. FRET hybridisation probes are two DNA 
probes designed to anneal next to each other, allowing fluorescence from one strand to 
be absorbed by the acceptor on the other strand, which then emits light at a third 
wavelength. For all real-time PCR using fluorescence technology, fluorescence output 
is plotted against cycle number, and the resulting threshold cycle (Ct) is proportional to 
the number of target copies present in the sample. Amplicon size (usually <200 bp), and 
use of specific thin-walled reaction tubes means results may be achieved in less than 
one hour (reviewed by Mackay 2004; Espy et al. 2006) 
 
1.4.12.3 Advantages and disadvantages  
The real advantages of this technique in contrast to conventional PCR are the reduced 
chance of contamination (closed tube system) and the speed to result with same day 
results possible. Real-time PCR is useful in the identification and detection of bacteria 
that require long culture times or are difficult to grow (e.g. Mycobacterium spp, 
Chlamydia spp, L. pneumophila) or where rapid discrimination is required (e.g. N. 
meningitidis). Genetic assays offer faster and therefore more cost-effective 
implementation of appropriate antibiotic therapy as well as infection control procedures, 
and also detect the presence of poorly or non-expressed (silent) genes difficult to detect 
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by phenotype. Real-time PCR allows quantification of the starting template to detect 
increased expression of genes normally expressed at low levels (reviewed by Espy et al. 
2006). 
The main disadvantage of real-time PCR at this time is the start up expense and 
expertise required which may negate its use in smaller laboratories. Test volume, 
fluorescence detection technology used, turnaround time for results, availability of staff 
with sufficient expertise, and equipment expense must be evaluated. Sample preparation 
time also can add considerably to cost, depending on the type of sample to be tested and 
the method used. A number of automated DNA extraction instruments are now 
commercially available. These vary in extraction method, cost and time requirements 
for extraction. The larger robotic systems require considerable throughput to be cost 
effective (reviewed by Espy et al. 2006). Commercial “real-time” kits usually include a 
DNA extraction procedure within the kit and although initially expensive, offer a rapid 
robust technology complete with appropriate controls, require minimal operator input 
and are now becoming more cost effective. The advantages and disadvantages of PCR 
vs conventional phenotypic testing have been comprehensively discussed (reviewed by 
Cockerill 1999; Mackay 2004; Yang and Rothman 2004; Espy et al. 2006). 
PCR primer design must ensure specificity of primer binding site for the gene 
to be amplified. However this is not always possible when genes are found in other 
genera or species, for example the vanB gene which, although it is predominantly found 
as a vancomycin resistance gene in enterococci, has also been detected in resident 
anaerobic flora of the human bowel (Ballard et al. 2005). 
Mutations in the primer-binding site may give false negative results. Broad-
based primers with degenerate sequences to rapidly detect unknown pathogens have 
been used to identify viruses (e.g. causative agent in SARS). This technique, described 
as a “molecular petri dish” potentially will identify existing infectious causes for 
diseases which are currently unknown (Yang and Rothman 2004) and may also be used 
to overcome false negative results from resistance gene mutations. 
Resistance to an antibiotic may arise from the development of point mutations, 
acquisition of a variety of different resistance genes, or due to variations in gene 
expression. Direct detection by genetic methods means that variably expressed or 
inducible genes are detected, as are those which may be more significant after transfer 
into a different genetic context. A classic example is detection of the staphylococcal 
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mecA gene where phenotypic susceptibility testing may vary due to heterogenous 
expression (reviewed by Yang and Rothman 2004). Another example is the necessity 
for genetic testing to detect blaIMP-4 in Enterobacteriaceae. These bacteria are often 
susceptible to carbapenems on phenotypic testing, unless additional mechanisms such as 
porin downregulation contribute to produce a resistant phenotype. Treatment with a 
carbapenem antibiotic on an apparently susceptible isolate with blaIMP-4 would 
potentially select for resistance and result in treatment failure (Espedido et al. 2005).  
The high sensitivity of PCR, especially real-time PCR, may detect low 
bacterial numbers and may also detect non viable bacteria in clinical and infection 
control screen samples (Paule et al. 2003). Conventional phenotypic methods take at 
least 72 h to result and require patients to be isolated for that period. Conversely, if the 
patient is not isolated, delayed notification of a positive result may allow dissemination 
of nosocomial pathogens. Low levels of colonisation, particularly in perineal sceen 
swabs, may be considered low risk, but antibiotic use will readily select for and allow 
overgrowth of colonised potential pathogens.  
Specimen to specimen carry over contamination is possible either between 
samples or from earlier PCR reactions. Separation of procedural steps (pre and post 
amplification) reduces the risk of aerosol cross contamination, particularly when 
samples potentially carry a high load of bacteria. Reagent preparation (master mix), 
sample processing (DNA extraction), addition of DNA to master mix, and amplification 
(thermocycling) should be separated, each with its own dedicated working materials. 
Negative controls included in the assay will also monitor contamination during the PCR 
(reviewed by Espy et al. 2006).  
False negative results may result from a relatively small sample volume used in 
the PCR reaction or be associated with the PCR processing (Yang and Rothman 2004). 
If the bacterial load in the sample is small relative to the volume used, false negatives 
may result (van Belkum et al. 2007). Brief culture of the sample prior to PCR, 
centrifugation, or introduction of capture probes all help to concentrate the DNA in a 
sample. Specimens such as faecal samples and some blood culture bottle additives 
(Fredricks and Relman 1998) are recognised as potentially having an inhibitory effect 
unless appropriate extraction is performed. Addition of target nucleic acid to the 
specimen prior to DNA extraction and the inclusion of an internal control will monitor 
DNA extraction as well as the PCR assay. 
1.4.13 Project Aims 
 
The aim of this project is to develop genetic methods to allow rapid detection of 
pathogens and antimicrobial resistance in critically ill and highly dependent patients. 
The initial trial will attempt to develop a rapid identification and resistance detection 
method for blood culture samples using a well-documented and well-characterised 
resistance gene, mecA, and a S. aureus-specific identification gene, nuc. The next step 
will be to develop a broth selection and multiplex PCR that would detect colonisation of 
patients with the most problematic nosocomial organisms at this institution, namely 
MRSA, Enterobacteriaceae with blaIMP-4, and MRAB. Lastly, aminoglycoside 
resistance will be examined as an example of an important phenotype. There is little 
information available on the genetic determinants encoding aminoglycoside resistance 
in Australia or the transmissibility of these genes apart from their association with the 
mobile ESBL phenotype. The aim is therefore to examine a subset of clinically 
significant aminoglycoside resistant strains and identify their resistance genes and 
potential transmissibility within the Enterobacteriaceae. Resistance in this family is less 
common, less predictable, and more likely to be due to acquisition of mobile 
aminoglycoside resistance genes than efflux, porin down regulation or chromosomal 
mutations. The long-term goal is to identify gene targets for rapid detection, then 
develop a multiplex PCR or microarray as a multiple gene analysis tool. Co-association 
with other resistant determinants may be useful if found to be predictable and definitive, 
as this may provide specific identifiers for some of the targets that are difficult to 
identify.  
 58
2 Chapter 2 
 
 
 
2.1 Materials and Methods 
 
2.2 Introduction 
The overall aim of this thesis to develop rapid methods for the detection of resistance in 
medically important bacteria was divided into 3 parts as described below. 
Chapter 3 describes the development of a rapid real-time PCR to detect methicillin-
resistant S. aureus in positive signalling blood cultures. DNA extraction from blood 
culture buffy coat was problematic with several protocols evaluated, before using the 
MagNA Pure robotic system for the 120 samples evaluated in this study. A duplex PCR 
using the Smart Cycler platform was developed and used to test samples for nuc and 
mecA genes.  
Chapter 4 describes the development of a selective broth and conventional multiplex 
PCR to detect the nosocomial pathogens of local importance at this institution. 
Combinations of ampicillin-cefoxitin and ampicillin-ceftazidime added to broth were 
evaluated for prior overnight incubation of perineal swabs, and the multiplex PCR 
optimised to detect blaIMP-4, blaOXA-23, mecA and femA genes. 
Chapters 5 and 6 describe a subset of aminoglycoside-resistant Enterobacteriaceae and 
the detection of the genes encoding for aminoglycoside resistance. Initially, cassette 
array PCR was used, then sequencing of resulting amplicons, and the design of specific 
primers. Plasmid transfer, to detect carriage of aminoglycoside resistance plasmids, was 
also performed. 
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2.2.1 Laboratory consumables 
 
Laboratory consumables were non-pyrogenic, individually wrapped (where applicable) 
and sterile. 
 
 
Table 2.1 List of laboratory consumables 
Laboratory product Source  
10 mL sterile screw cap (yellow-top) tubes Sarstedt  Mawson Lakes, 
Australia 
Aerosol barrier tips (20, 200, 1000 μL) Astral  Gymea, Australia 
BACTEC Aerobic/F bottles Becton Dickinson Sparks, MD, USA 
BACTEC Anaerobic Lytic/10 bottles Becton Dickinson Sparks, MD, USA 
Cotton swabs/wooden applicator sticks Multigate Medical NSW, Australia 
Eppendorf UVette® Eppendorf AG Hamburg, Germany 
Flat cap PCR tubes (0.5 mL) Astral  Gymea, Australia 
Hybond™-C Extra Nitrocellulose Amersham  Buckinghamshire, UK 
Microfuge tubes (1.5 and 2 mL-Safe-lock) Eppendorf Hamburg, Germany 
Minisart syringe filters (0.2 μM) Sartorius AG Hannover, Germany 
Parafilm Pechiney Plastics Menasha, WI, USA 
Pipette tips (200 and 1000 μL) Sarstedt  Mawson Lakes, 
Australia 
Plastic spreaders Pacific Lab. Products  Victoria, Australia 
Pre-sterilised 10 mL bottles with Titus caps Mawson Lakes, 
Australia 
Sarstedt  
Bacto Laboratories  NSW, Australia Samco® transfer pipettes 
Serum separating tubes (SSTTM Advance) Becton Dickinson Sparks, MD, USA 
Thermal paper for video copy processor Mitsubishi Electric  Kyoto, Japan 
Weigh trays Sarstedt  
 
 
Mawson Lakes, 
Australia 
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2.2.2 Laboratory Equipment 
 
Table 2.2 List of equipment used in this work 
Equipment Manufacturer Location 
BACTEC 9240 Becton Dickinson Sparks, MD, USA 
BD Phoenix  Becton Dickinson Sparks, MD, USA 
BioPhotometer Eppendorf Hamburg, Germany 
Cepheid Smart Cycler II® Cepheid  Sunnyvale, CA, USA 
Certomat M rotary shaker B. Braun Melsungen AG West Germany 
DensiChek densitometer bioMérieux Durham NC, USA 
Dry block heater Thermoline L+M Sydney, Australia 
Electrophoresis tank Biorad Sub-cell® GT Regents Park, NSW, Australia 
Heraeus biofuge Kendro  Langenselbold, Germany 
Mitsubishi P91 video copy 
processor 
Mitsubishi Electric Tokyo, Japan 
PC – 960C thermal cycler Corbett Research  Sydney, Australia 
Qik Spin Edwards Instruments Narellan, Australia 
SANYO MCO-17AIC Sanyo Electric Tokyo, Japan 
Spintron centrifuge GT-175A Spintron  Dandenong, VIC, Australia 
UviSave transilluminator UVItec  Cambridge, England 
UviTec transilluminator UVItec  Cambridge, England 
Vortex mixer Ratex Instruments  Boronia, Australia 
2.2.3 Chemicals and reagents 
 
All chemicals and reagents were of analytical or molecular biology grade. 
 
Table 2.3 List of chemicals and reagents 
Chemical/Reagent Source Location 
Agarose 1 Amresco Solon, Ohio, USA 
Boric acid Amresco Solon, Ohio, USA 
CHROMagar Orientation Oxoid Paris, France 
D-(+)-Trehalose dihydrate Sigma  St Louis, USA 
Ethidium bromide Amresco Solon, Ohio, USA 
Ethyl alcohol (Ethanol) Merck  Kilsyth, Australia 
Ethylene diamine tetra acetic acid (EDTA) Amresco Solon, Ohio, USA 
Glycerol Amresco Solon, Ohio, USA 
Isopropyl alcohol Amresco Solon, Ohio, USA 
LB broth (Lennox L Broth) Sigma  St Louis, USA 
Lysozyme (egg white) Research Organics  Cleveland, Ohio, USA 
Methyl alcohol (methanol) Merck  Kilsyth, Australia 
Mueller Hinton agar Oxoid  Hampshire, England 
Nutrient agar Oxoid  Hampshire, England 
Nutrient broth Oxoid  Hampshire, England 
Tris Amresco Solon, Ohio, USA 
Tris-HCL Amresco Solon, Ohio, USA 
Triton X-100 Ajax  Auburn, NSW, Australia 
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2.2.4 Preparation of buffers, media and solutions 
 
Table 2.4 Buffers, media and solutions 
Buffer/media/solution Composition 
5 x Tris-Borate-EDTA (TBE) Buffer 
 
 
0.89 M Boric Acid 
0.01 M EDTA 
0.45 M Tris 
 
Blood agar plates (HBA) Columbia Blood Agar base No. 2 
5% defibrinated horse blood  
(Hunter Antisera, Jesmond, Australia) 
 
Chromogenic agar 33 g CHROMagar Orientation agar 
Water to 1 L. Autoclave 121ºC 15 min 
Store plates away from light 
 
Coagulase test Rabbit plasma (BIO-RAD). Add 10 mL solvent 
to vial of freeze-dried rabbit plasma, shake gently 
and aliquot in 0.5 mL volumes 
 
Deoxyribonuclease Agar (DNase) 39 g DNase agar base to 1 litre with water 
Boil to dissolve the medium completely 
Autoclave at 121ºC 15 min 
 
EDTA 0.5M pH 8.0 93.06 g dissolved in approx 350 mL distilled 
water. Add NaOH pellets, dissolve until pH 8.0 
Make up to total volume 500 mL 
Autoclave 121ºC 15 min 
 
Enzymatic lysis buffer 20 mM Tris-HCl pH 8.0 
2 mM EDTA 
1.2% Triton x-100 
Add 20 mg/mL lysozyme to required volume 
immediately before use in extraction 
 
Glycerol Nutrient broth 20% 1.3 g Nutrient broth base 
Water to 80 mL 
Add 20 mL glycerol, mix well 
Autoclave at 121ºC 15 min 
 
Lennox L Broth  10g LB broth base (5% NaCl, 10% tryptone, 5 % 
yeast extract Sigma) Water to 500 mL. Autoclave 
at 121ºC 15 min 
 
Mannitol Salt agar (MSA) Oxoid CM85 Oxoid Manual 5th edition 1982. 111 g MSA base 
to 1 L of water. Autoclave at 121ºC 15 min 
 
Methicillin-Aztreonam-Mannitol Salt 
agar (MAMSA) 
57 g Brain Heart Infusion broth, to 1 L of water 
Heat to dissolve. Autoclave at 121ºC 15 min, add 
methicillin and aztreonam to final concentration 
of 5 and 8.3 µg/mL respectively (Perry et al. 
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Buffer/media/solution Composition 
1998) 
Mueller Hinton agar (MHA) 38 g Mueller Hinton agar base to 1 L 
Bring to boil to dissolve the medium completely 
Autoclave at 121ºC 15min 
 
Nutrient Agar 14 g Nutrient agar base, water to 500 mL 
Autoclave at 121ºC 15 min 
Cool to 50ºC before adding antibiotic 
Pour plates (20 mL/plate). Store at 4ºC 
 
Nutrient Broth 13 g Nutrient broth base 
Water to 1 L. Autoclave at 121ºC 15 min 
 
TAE Buffer 40 mM Tris acetate 
2 mM sodium EDTA 
Adjust to Ph 7.9 using glacial acetic acid 
Autoclave 121ºC 15 min 
 
Trehalose agar D-(+)-Trehalose 
dihydrate 
30 g BACTO peptone 
15 g NaCl 
45 g BACTO agar 
75 mL 0.2% Bromocresol purple 
30 g trehalose 
Water to 3 L, adjust pH to 6.4 
Autoclave at 121ºC 15 min 
(Stevens and Jones 1984) 
 
VG agar CHROMagar base  
 Cool to 50ºC before adding antibiotics 
 Gentamicin 8 µg/mL 
Vancomycin 4 µg/mL 
 
VGI agar 
 
 
CHROMagar base 
Cool to 50ºC before adding antibiotic 
Gentamicin 8 µg/mL 
Vancomycin 4 µg/mL 
Imipenem 10 µg/mL 
 
 
2.2.4.1 Preparation of Lennox L (LB) selective broth  
Lennox L broth was prepared as above (Table 2.4). Antibiotic solutions were prepared 
as described in Table 2.5 for same day use. 40 µL of the 10 mg/mL stock solution added 
to 100 mL broth gave a working concentration of 4 µg/mL. The volume of antibiotics 
added was adjusted proportionally when higher concentrations of antibiotic were 
required. After thorough mixing, 2 mL aliquots were dispensed into pre-sterilised 10 
mL bottles with Titus caps or 10 mL aliquots into sterile yellow-topped plastic tubes for 
inoculation and overnight incubation. 
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2.2.5 Antimicrobial agents 
All antibiotic solutions were sterilised by passing thorough a Minisart 0.2 µM filter. 
When antibiotic-containing plates were required, the agar was cooled to 50ºC, 
antibiotics added and mixed well before pouring plates (20 mL/plate). Plates were used 
the same day or stored at 4ºC. 
 
Table 2.5 Antibiotics used in mating experiments and selective broth development 
Antibiotic Source Stock concentration 
mg/mL 
Working concentration 
mg/L 
Mating experiments    
Ampicillin (AMP) CSL Biosciences,  0.1 g dissolved in 10 mL 
water (10 mg/mL) 
10 
Gentamicin sulfate 
Sol. BP for injection  
Pharmacia Australia  40 mg/mL 10 
Rifampicin Sigma-Aldrich  0.1 g dissolved in 10 mL 
methanol (10 mg/mL) 
80 
Nalidixic acid Sigma-Aldrich  25 mg dissolved in 1 mL 
0.5 M NaOH (25 mg/mL) 
25 
 Selective broth development   
Ampicillin  CSL Biosciences  0.1 g dissolved in 10 mL 
water (10 mg/mL) 
8, 12, 16 
(AMP) 
Cefoxitin sodium salt 
(FOX) 
Sigma-Aldrich  0.05 g dissolved in 10 mL 
water (5 mg/mL) 
4, 8 
Ceftazidime hydrate 
(CTZ/CAZ) 
Sigma-Aldrich  0.1 g dissolved in 2 mL of 
0.1N NaOH, then made up 
to a final volume of 10 mL 
with water  (10 mg/mL) 
 
4, 6, 8 
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2.2.6 Enzymes 
Enzymes used in this work. Reaction buffers associated with the enzyme were provided 
by the manufacturer. 
 
Table 2.6 Enzymes 
Enzyme Source  
RNAse A Roche Diagnostics  Indianapolis, USA 
Taq DNA polymerase Bioline  Alexandria, NSW, Australia 
Lysozyme, egg white Research Organics  Cleveland, Ohio, USA 
HindIII (20,000 U/mL) New England BioLabs Genesearch, QLD, Australia 
SphI (1,250 U/mL) New England BioLabs Genesearch, QLD, Australia 
BsrI (5,000 U/mL) New England BioLabs Genesearch, QLD, Australia 
 
 
2.2.7 Molecular weight ladders 
 
Table 2.7 Molecular weight markers 
Ladder Source Bands 
1Kb DNA ladder Gibco™ Services, Mount 
Waverly, Australia 
75, 134, 154, 201, 220, 296, 
344, 396, 506, 517, 1018, 1636, 
2036, 3054, 4072, 5090, 6106, 
7125, 8144, 9162, 10180, 
11198, 12215 bp.  
 
Hyperladder 1 
 
Astral Scientific, NSW, 
Australia 
 
200, 400, 600, 800, 1000, 1500, 
2000, 2500, 3000, 4000, 5000, 
6000, 8000, 10,000 bp. 
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2.2.8 Bacterial strains 
 
Table 2.8 PCR-control and recipient strains in mating experiments 
Isolate 
(Species) 
Strain name or 
identifier 
Features Sources 
 
E. coli  
 
DH5α a 
 
deoR, endA1, gyrA96, hsdR17, (rk-
mk+), recA1, relA1, supE44, thi-1, 
Δ(lacZYA-argF), φ80lacZ 
ΔM15Fλ  
 
Cursaro, C.; University 
of Adelaide, Dept of 
Microbiology and 
Immunology 
E. coli  UB5201Rf a Rifampicin variant of UB5201  Partridge, S.; CSIRO 
Molecular Sciences (de 
la Cruz and Grinsted 
1982) 
E. coli  UB1637 R388 b TmpR SuR Tra+; intl1 in In3  Partridge, S.; CSIRO 
Molecular Sciences 
E. coli  DH5α pMAQ612 b ApR; intl2 from Tn7, cloned into 
pUC18 
H. Stokes, Macquarie 
University 
E. coli  DH5α pSMB731 b  ApR; intl3 Partridge, S.; CSIRO 
Molecular Sciences 
(Arakawa et al. 1995) 
C. freundii  02.067.0333 (CI38) c Tn1696 control (344bp) clinical isolate (this 
institution) 
E. coli  02.014.0314 (CI20) c  Tn21 control (717bp) clinical isolate (this 
institution) 
Perineal flora  02.037.3042 (Pt 11) c  Tn1721 control (767bp) Lysate prepared from 
growth of mixed flora 
from a perineal screen 
swab 
E. coli JIBE402 d blaIMP-4, qacG2, aacA4, catB3 in a 
pGEM®-T Easy vector system 
(lacZ orientation).  
B. Espedido 
UB5201Rf  pJIBE401 d  Citrobacter amalonaticus 
05.211.3927 blaIMP-4 transferred to 
Escherichia coli UB5201Rf 
B. Espedido 
a  recipient strains used in mating experiments, Chapter 5.  
b  Control strains used for class 1, 2 and 3 intgrase gene PCR. 
c  Transposon PCR controls. Isolates sourced from this institution.  
d bla IMP-4 controls for multiplex PCR. (Chapter 4). 
ApR Ampicillin resistant 
Table 2.9 Bacterial strains used in this thesis 
Sample  
identification 
Laboratory 
identifier 
Key characteristics Abbreviations 
(this thesis) 
Alternate 
nomenclature 
and source 
A. baumannii   99-152.2357 blaOXA-23 positive. Resistant to 
ampicillin, cefoxitin, ceftazidime 
and carbapenems 
MRAB 
pcAB 
WH a  
C. freundii 05.075.3046 Resistant to gentamicin and 
tobramycin 
JIE b 23 WH 
C. albicans ATCC 60193 Candida albicans (Robin) 
Berkhout, anamorph 
 ATCC c 
E. aerogenes 04.159.2423 Resistant to gentamicin, 
tobramycin ampicillin, cefoxitin. 
Susceptible to ceftazidime 
 
A 7 WH 
E. cloacae 04.205.1107 Resistant to gentamicin and 
tobramycin 
A d 26 WH 
E. cloacae 04.220.1622 Resistant to gentamicin and 
tobramycin 
A29 WH 
E. cloacae 04.219.1098 Resistant to gentamicin and 
tobramycin 
A30 WH 
E. cloacae 04.224.3503 Resistant to gentamicin and 
tobramycin 
A32 WH 
E. cloacae 04.169.3883 Resistant to gentamicin and 
tobramycin 
A9 WH 
E. cloacae 04.174.3518 Resistant to gentamicin and 
tobramycin 
JU b 10 ICU 1.81; 
EI3518, WH 
E. cloacae 04.333.1573 Resistant to gentamicin and 
tobramycin 
LT b 30 EI1573, WH 
E. coli  04.119.2264 Resistant to gentamicin and 
tobramycin 
ICU e 29 KK7, 1.29; 
WH 
E. coli 05.067.0187 Resistant to gentamicin and 
tobramycin 
JIE11 WH 
E. coli  05.077.1647 Resistant to gentamicin and 
tobramycin 
JIE22 WH 
E. coli  05.059.1317 Resistant to gentamicin and 
tobramycin 
JIE3 WH 
E. coli  04.014.3062 Resistant to amikacin, tobramycin. 
Susceptible to gentamicin 
 
LT39 WH 
E. gergoviae 04.192.0899 Resistant to gentamicin and 
tobramycin 
ICU64 WH 
E. hormaechei 05.059.1356 Resistant to gentamicin and 
tobramycin 
JIE2 WH 
E. faecalis ATCC 29212 Susceptible to ampicillin. Resistant 
to cephalosporins 
 ATCC 
E. faecium  ATCC 51299 Low-level vancomycin resistant 
vanB. Susceptible to ampicillin. 
Resistant to cephalosporins 
VRE ATCC 
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Sample  
identification 
Laboratory 
identifier 
Key characteristics Abbreviations 
(this thesis) 
Alternate 
nomenclature 
and source 
E. coli ATCC 25922 Susceptible to ampicillin, 
cephalosporins and gentamicin  
 ATCC 
K. oxytoca  05.064.3626 Resistant to gentamicin and 
tobramycin 
JIE13 WH 
K. pneumoniae 04.037.2399 
 
Resistant to gentamicin and 
tobramycin 
A60 WH 
K. pneumoniae 04.222.3777 Resistant to gentamicin and 
tobramycin 
ICU46 KK15, WH 
K. pneumoniae 05.071.2120 Resistant to gentamicin and 
tobramycin 
JIE14 WH 
K. pneumoniae 05.076.2856 Resistant to gentamicin and 
tobramycin 
JIE21 WH 
K. pneumoniae 04.186.1241 Resistant to gentamicin and 
tobramycin 
LT12 WH 
K. pneumoniae ATCC 13883 Susceptible to cephalosporins and 
gentamicin. Resistant to ampicillin; 
blaIMP-4 negative  
 ATCC 
K. pneumoniae 03.004.1239 blaIMP-4 positive; carbapenem 
resistant wt resistant to ampicillin, 
cefoxitin and ceftazidime  
CR-KP 
pcKP 
JU 19 
KO3, Kp1239 
BH  f 
Methicillin-resistant S. 
aureus   
05.031.1634 Methicillin resistant; mecA, nuc, 
femA positive. Resistant to 
ampicillin, cefoxitin and 
ceftazidime 
MRSA 
pcMRSA 
WH  
Methicillin-resistant S. 
aureus  
05.031.3781 Non multi-resistant; mecA, nuc, 
femA  positive. Resistant to 
ampicillin, cefoxitin and 
ceftazidime 
CA-MRSA WH  
Methicillin-resistant S. 
epidermidis 
05.030.1659 Methicillin resistant; mecA 
positive. Resistant to ampicillin, 
cefoxitin and ceftazidime 
MR-CoNS, 
pcRSE 
WH  
P. aeruginosa ATCC 27853 Susceptible to gentamicin, and 
ceftazidime. Resistant to cefoxitin. 
 ATCC 
S. aureus ATCC 25923 mecA negative, nuc, femA positive. 
Susceptible to ampicillin, cefoxitin 
and ceftazidime 
MSSA 
pcMSSA 
ATCC 
S. epidermidis  ATCC 12228 mecA negative; resistant to 
ampicillin. Susceptible to 
ceftazidime 
MS-CoNS 
pcSE 
ATCC 
a WH = Westmead Hospital (this institution).  
b Isolates collected based on their multi-resistance profile from the Microbiology Laboratory. 
c American Type Culture Collection, Rockville, MD.  
d Isolates collected for Australian Group on Antimicrobial Resistance (AGAR 2004).  
e Isolates were collected from patients in the ICU from April 2004 to August 2005. 
f Blacktown Hospital. Sydney region. 
2.2.8.1 Isolates characterised in Chapters 5 and 6 (Table 2.9) 
 
N.B. Where an isolate is included in more than one group, note is made in the text. 
 
2.2.8.1.1 
2.2.8.1.2 
2.2.8.1.3 
Group 1: Study collection of isolates 
23 Enterobacteriaceae (Group 1) resistant to either one or more of the aminoglycosides 
gentamicin, tobramycin or amikacin were collected from the clinical microbiology 
laboratory, Westmead Hospital, for the purpose of this study and were analysed using 
Phoenix NMIC/ID-101 Gram-negative identification and susceptibility panels. Where 
possible, isolates deemed to be clinically significant from sites such as urine, blood, 
wound or sputum were collected. Three isolates with a previously identified common 
cassette array carrying four resistance cassettes (blaIMP-4-qacG2-aacA4-catB3, GenBank 
AJ609296) were included to see if multiple aminoglycoside resistance determinants 
were present in addition to the aminoglycoside resistance gene aacA4 (aac(6')-Ib) 
(gentamicin, not amikacin resistant).  
 
Group 2: Australian Group on Antimicrobial Resistance (AGAR)  
The AGAR group co-ordinates an Australia-wide annual collection of clinically 
significant Enterobacteriaceae. Each laboratory tests their collection using identical 
protocols to detect trends in resistance. In 2004 this institution collected and tested 99 
clinically significant isolates (50 Enterobacter spp 27 Klebsiella spp and 22 E.coli) 
from in-patients (including ICU patients) using custom made MicroScan panels (Dade 
Behring). Seven isolates from the AGAR study were selected for their resistance to 
either gentamicin and/or tobramycin and included in the study Group 1 (A7, A9, A26, 
A29, A30, A32, A60). Amikacin had not been included in the MicroScan panels so 
resistance to this antibiotic was not tested for in this group. 
 
Group 3: ICU study group  
A 16-month collection (2004-2005) of clinically significant isolates from patients in 
ICU at this institution was available. There were eight gentamicin and/or tobramycin 
resistant isolates and no amikacin resistant isolates from 158 isolates (39 Enterobacter 
spp., 49 Klebsiella spp., and 70 E.coli) from this collection. Three isolates were selected 
for their resistance to either gentamicn and/or tobramycin and were included in the 
study Group 1 (ICU29, ICU46, ICU64). 
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2.2.9 Preparation of bacterial strains  
 
2.2.9.1 Storage of strains 
Fresh 24-hour 5% horse blood agar (HBA) cultures of isolates were frozen in 20% 
glycerol nutrient broth and stored at -70°C until required.  
 
2.2.9.2 Subculture of frozen stocks 
Frozen stock cultures stored at -70°C were sub-cultured on to fresh HBA plates 
manufactured by the Media department at CIDM as required, and then incubated in 
aerobic conditions at 35°C for 18 h. 
 
2.2.9.3 Preparation of whole cell lysates 
Bacterial suspensions from 24-hour plate cultures were made in distilled water to 
achieve a McFarland standard optical density of 2.0 using a DensiChek densitometer. 
One mL aliquots were transferred to 1.5 mL microcentrifuge tubes and incubated in a 
dry block heater at 96°C for 30 min and stored at -20°C for future use. Templates from 
overnight broth cultures were prepared by transferring 500 μL of broth into 1.5 μL 
microcentrifuge tubes, which were heated as described above and stored at -20°C. 
When required as PCR template, the samples were thawed, vortexed, and briefly spun 
before use in the PCR. 
 
2.2.9.4 Preparation of inocula for “spiking” of Bactec blood culture bottles 
Controls (Table 2.9) were incubated in LB broth for inoculation (“spiking”) of 100 CFU 
into sterile paired BD Bactec Plus Aerobic/F and Bactec Anaerobic Lytic/10 blood 
culture bottles. After overnight growth, broths were diluted to an estimated 100 
CFU/mL and inoculated into bottles along with 5 mL of fresh sterile human blood. 
 
2.2.9.5 Preparation of bacterial dilutions (Chapter 4) 
24-hour bacterial cultures on HBA were suspended in saline to achieve an optical 
density of 0.5 McFarland (1.5 x 108 CFU/mL) using a DensiChek densitometer and 
mixed well. An initial dilution was made in saline to 1.0 x 108 CFU/mL, then serial 
dilutions to 1.0 x 100 CFU/mL. 100 µL of each well-mixed dilution of the bacterial 
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suspension was added to a 2 mL aliquot of broth plus antibiotic and incubated for 18 h 
at 35°C in aerobic conditions on a Certomat M Rotary Shaker. 
 
2.2.9.6 Confirmation of inocula  
To confirm the actual inocula, (vs the calculated inocula, 2.1.9.5) 100 µL of each 
dilution was spread on to a fresh HBA plate at the time of the broth inoculation, 
incubated overnight at 35°C and a colony count performed the next day. Where this was 
done, the CFU/mL was adjusted to correlate with the plate count CFU/mL. 
 
2.2.9.7 Turbidity and viability checks of overnight selective broth cultures  
A visual turbidity check of all tubes was made by comparison with known positive and 
negative control broths. To perform a viability check, an aliquot of 100 µL was taken 
from all broths, inoculated onto HBA plates, spread with a disposable spreader, then 
incubated overnight at 35°C. Plates were checked for no growth, or growth of the 
correct strain the next day. 
 
2.2.9.8 Bacterial counts: blood culture bottles  
An aliquot (100 µL) of well mixed blood-broth and “buffy coat” was sequentially 
diluted in sterile saline, (dilutions ranging from 10-1 to 10-8), mixed well and 100 µL of 
each dilution spread evenly over the surface of a 5% HBA plate using a disposable 
spreader. After overnight incubation at 35oC, colony counts were performed on the 
plates with clearly defined colonies and the CFU/mL of starting inocula was calculated. 
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2.2.10 Identification and susceptibility testing of bacterial isolates 
Table 2.10 Commercially available susceptibility tests 
Name Company Address 
BD Phoenix™  PMIC/ID-53 a Becton Dickinson  Sparks, MD USA 
BD Phoenix™ NMIC/ID-101b Becton Dickinson  Sparks, MD USA 
Vitek2 AST-GN05 b bioMérieux  Durham NC USA  
Etest strips AB Biodisk Solna, Sweden 
Antibiotic discs Bio-Rad Laboratories Regents Park, NSW, Australia 
Oxacillin disc (1 µg) Bio-Rad Laboratories Regents Park, NSW, Australia 
a Gram-positive identification and susceptibility card. 
b Gram-negative identification and susceptibility card. 
 
2.2.10.1 Preparation of inocula for Etests and Kirby-Bauer susceptibility tests 
A fresh 24-hour HBA plate culture was used to prepare a 0.5 McFarland suspension in 
saline. A cotton wool swab was immersed in the suspension, excess liquid removed by 
wringing out on the side of the tube, and then a three-way streaking system was used to 
evenly inoculate the surface of a MHA plate. After 15 min, either commercially 
available discs or Etest strips were placed on the plate using sterile forceps or the 
applicator provided, following manufacturer’s instructions, and then incubated at 35°C 
for 18 h. CLSI interpretive guidelines (CLSI 2005) were followed after reading zone 
diameters on the Kirby-Bauer plates, and manufacturer’s instructions followed for 
reading and interpreting the Etest strips. 
 
2.2.10.2 Phoenix and Vitek2 automated identification and susceptibility systems 
 
2.2.10.2.1 Testing of strains  
Two automated systems were used to test clinically significant Gram-negative bacteria. 
Prior to 2005, the Vitek2 Colorimetric Automated Microbiology System was in place in 
the Microbiology department, after which the BD Phoenix automated Microbiology 
system was installed.  
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The Vitek2 includes an instrument, software, and disposable cards. The plastic 
identification card has 64-wells that contain 47 modified conventional and chromogenic 
substrates. Colorimetric measurements are taken every 15 min for a maximum 
incubation period of 10 h. The system uses algorithms to look at a variety of parameters 
and test conditions to ensure accurate test results and combines identification and 
susceptibility results in an advanced “EXPERT” system (AES).  
The Phoenix includes an instrument, software, disposable panels, broths for ID 
and AST, and an AST indicator. The identification system uses modified conventional 
fluorogenic and chromogenic substrates and is monitored every 20 min for a positive or 
negative reaction up to 16 h. Antimicrobial resistance is detected by growth in the 
presence of the antimicrobial as determined by a colorimetric redox indicator. The 
Phoenix includes an advanced BDXpert System to aid in the identification of AST 
errors or unusual results. There is an inbuilt ESBL detection algorithm using results 
from 5 different antibiotic combinations, and MIC interpretation (see Appendix D) is 
also influenced by organism identification, with the MIC cut-off for resistance varying 
according to the isolate ID.  
Card inoculation requires a fresh 24-hour HBA plate culture to prepare a 0.5 McFarland 
suspension in saline using the DensiChek densitometer for the Vitek2 and in the 
provided medium using the PhoenixSpec nephelometer for the Phoenix system. 
 
2.2.10.2.2 Interpretation of susceptibility results 
Results are given as an MIC value, followed by an interpretation of that result which 
may be “susceptible”, “intermediate” or “resistant”. An “intermediate” result is due to 
an MIC that falls between susceptible and resistant, and may be useful dependent upon 
various factors such as site and identification of clinical isolate. For example, an 
antibiotic that is excreted via the urinary tract may be effective in treatment of a urinary-
tract infection in spite of an “intermediate” profile. Following “expert” rules, a 
“susceptible” or “intermediate” result may be automatically corrected to resistant. For 
example, an “intermediate” MIC to Augmentin for an ESCHAPPM organism will 
automatically be corrected to resistant, due to knowledge of the resistance profiles of 
this group, and to follow normal therapeutic guidelines. 
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2.2.10.3 Rapid identification of blood culture staphylococcal isolates 
When growth was detected in the BACTEC 9240 automated continuous monitoring 
system in either clinical blood culture specimens containing Gram-positive cocci 
consistent with staphylococci, or from “spiked” bottles, 5 mL aliquots were removed. 
Aliquots were centrifuged (1250 g, 15 min) in a serum separating tube and the 
leucocyte-rich “buffy coat” retained. After aspiration of supernatant, 1 mL of “buffy 
coat” was mixed for direct inoculation of plates and for Gram-staining. The “buffy 
coat” from clinical samples and control strains was inoculated onto HBA for 
identification, and confirmation of purity. An aliquot of “buffy coat” was used to 
inoculate a rabbit plasma coagulase tube test (Bio-Rad, Marnes-la Coquette, France), 
Deoxyribonuclease test (Dnase), Mannitol and Trehalose fermentation agar plates, 
growth on Methicillin-Aztreonam-Mannitol-Salt Agar (MAMSA), and CLSI (Clinical 
and Laboratory Standards Institute, formerly NCCLS) susceptibility test with a 1 µg 
oxacillin disc. Isolates that were coagulase, DNAse, mannitol and trehalose positive 
were identified as Staphylococcus aureus. Resistance to methicillin was determined by 
growth on the MAMSA plate and additionally by growth within the CLSI-
recommended zone around the oxacillin disc on a Mueller Hinton agar plate after 
overnight incubation at 35oC. This was confirmed using the Phoenix Gram-positive 
identification and susceptibility card NMIC/ID-53. 
Table 2.11 Characteristics and sources of the control plasmids used in plasmid 
preparations in this study 
Plasmid Background Organism Features Source/Reference 
E. coli  A. Lee, School of 
Medicine, Stanford 
University (Lee and 
Falkow 1998) 
pANT-5  GFP mut 3 in pcom100; 
sm10λpir; GFP, Kan cartridge 
and ampicillin resistance 
gene; AmpR/KanR/green; 10.8 
kb 
 
(Thorsted et al. 1998) 
(GenBank U67194) 
R751 53 kb E. coli K12 host  
R934 
 
E. coli K12 host 72 kb (Hedges et al. 1975) 
pCACTUS  E.  coli DH5α Low-copy, pSC101 derived R Morona, Dept of 
Microbiology and 
Immunology, University 
of Adelaide. (Ogunniyi et 
al. 1997) 
 
 
 
2.2.11 Oligonucleotide primers and probes 
 
2.2.11.1 Primers used in this study for PCR development 
Where possible, published primer pairs were used, otherwise primers were designed as 
part of the study. Database searches and multiple alignments were carried out using the 
BioManager CLUSTALW program (http://www.angis.org.au/). Where there was 
sufficient homology, either the Primer 3 program was used to assist in primer selection 
(http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi) or choices were made 
manually and inserted into the Sigma program http://www.sigma-
genosys.com/calc/DNACalc.asp to calculate suitability. 
Primers and probes were manufactured by Sigma Proligo (Sigma-Aldrich Australia 
Ltd), or Geneworks Australia, and were diluted with sterile distilled water to a 
concentration of 100 μM and stored at –20º C. 
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Table 2.12 Oligonucleotide primers used in this study for conventional PCR 
Primer 
Name a Sequence (5' – 3') 
Init 
Time 
Ann 
(ºC) 
Ext 
Time Cycles 
Reference 
/amplicon 
(bp) 
hep58 TCA TGG CTT GTT ATG ACT GT 
hep59 GTA GGG CTT ATT ATG CAC GC 
30 s 
47 for 
45 s 
4 min 35 (White et al. 
2000) 
RH68/205 GTG GGT CGA TGT TTG ATG TT 
RH206/69 
GCT GTG AGC AAT TAT GTG CTT 
AGT GC 
30 s 
55 for 
45s 
4 min 37 Courtesy of R. 
Hall 
 
Int1F 
Int1R 
int2F 
int2R 
int3F 
int3R 
CAG TGG ACA TAA GCC TGT TC 
CCG AGG CAT AGA CTG TA 
CAC GGA TAT GCG ACA AAA AGG T 
GTA GCA AAC GAG TGA CGA AAT G 
(Koeleman et 
al. 2001) 
 
GCC TCC GGC AGC GAC TTT CAG 
ACG GAT CTG CCA AAC CTG ACT 
1 min 
59 for 
1 min 
1 min (Mazel et al. 
2000) 
35 
 
(Mazel et al. 
2000) 
mecAF 
mecAR 
TGG CTA TCG TGT CAC AAT CG (Vannuffel et 
al. 1995)  310 CTG GAA CTT GTT GAG CAG AG 
femAF 
femAR 
CTT ACT TAC TG (G) C TGT ACC TG (Vannuffel et 
al. 1995)  686 ATG TCG CTT GTT ATG TGC 
IMP-F1 
IMP-R1 
GGT TTG GTG GTT CTT GTA AA 
 
GTT TCA AGA GTG ATG CGT C 
(Espedido and 
Iredell)  520 
50 for 
45 s 
30 s 2 min 
Oxa23A GAT GTG TCA TAG TAT CGT CG 
Oxa23B TCA CAA CAA CTA AAA GCA CTG 
30 
(Afzal-Shah et 
al. 2001)  
1016 
fem2F AAT AAT AAC GAG GTC ATT GC 
30 s 
50 for 
45 s 
2 min 30 
fem2R TTT TTA  TTT TCA GGA CGT TT This study 
aadBF3 GAC ACA ACG CAG GTC ACA TT 
30 s 
55 for 
30 s 
1 min 35 
aadBR3 CGC ATA TCG CGA CCT GAA AGC 
(Kim et al. 
2004) 
aac6in-F ACT CAG GTG TTA GCC AGA CAA C 
30 s 
55 for 
30 s 
1 min 35 
aac6in-R CGT AAG CAA GAA CCG TGA AAC 
S. Partridge 
aac(6')-IIc 3F CCC AAT CCT ACA TCG CAC TT 
aac(6')-IIc 3R CCA CTT CCC CTT GAT TTT GA 
55 for 
45 s 
2 min 35 Appendix A 
354 
30 s 
aac(6')-IIc 4F 
(used with 
aac(6')-
IIc3R) 
TGC CGC AAT AGT TCT ACG AG 30 s 
55 for 
45 s 
2 min 35 This study 
562 
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Primer 
Name a Sequence (5' – 3') 
Init 
Time 
Ann 
(ºC) 
Ext 
Time Cycles 
Reference 
/amplicon 
(bp) 
aac(6')-II F 
consensus 
CAC ATH GTY GAR TGG TGG 
30 s 
50 for 
45 s 
2 min 35 
aac(6')-II R 
consensus 
CCK GCC TTC TCR TAG CAG 
Appendix B 
aac(3)-IIF 
consensus 
CGT ATG AGA TGC CGA TGC 
30 s 
55 for 
45 s 
2 min 35 
aac(3)-IIR 
consensus 
AAG ATA GGT GAC GCC GAA C 
Appendix C 
aac(3)-IIc F GACCGATCACCCTACGAG 
30 s 
55 for 
45 s 
1 min 35 This study aac(3)-IIc R CGAAATGCTTCTCAAGATAGG 
aadA2R CAA GGG TGA CTT CTA TAG 30 s 
48 for 
45 s 
2 min 35 J Valenzuela  
ERIC1R ATG TAA GCT CCT GGG GAT TCA C 51 for 
1 min 
30 s 2 min 35 AAG TAA GTG ACT GGG GTG AGA 
GCG 
ERIC2a 
(Versalovic et 
al. 1991) 
Transposon 
SP1 
Transposon 
Tn3P-F 
ATC CTG GCG GAT TCA CTA CC 
GGG TTC TGG TCG AAG CTG 
1 min 
50 for 
1 min 
1 min 
30 s 
35 S. Partridge  
 
Imp-BE 1 CAY GGT TTG GTG GTT CTT GTA A 
Imp-BE 2 CCT TTA ACV GCC TGY TCT YMT 
30 s 
52 for 
45 s 
1 min 35 B Espedido  
AACA4F TGA CCT TGC GAT GCT CTA TG 
30 s 
55 for 
30s 
30 s 35 
AACA4R CGT TTG GAT CTT GGT GAC CT 
This study 
CTXM1-F AAA AAT CAC TGC GCC AGT TC 
CTXM1-R AGC TTA TTC ATC GCC ACG TT 
(Woodford et 
al. 2006)  415 
CTXM9-F CAA AGA GAG TGC AAC GGA TG 
30 s 
55 for 
30 s 
30 s 35 
CTXM9-R ATT GGA AAG CGT TCA TCA CC 
(Woodford et 
al. 2006)  205 
CAA TGT GTG AGA AGC AGT CTA 
AA IsEcp1IR-F 
Z.Zong 5' orf 903-R 
(CTX-M-9 
group) 
CGG TTG ATG AGG GCT TTA TT 1 min 52 for 1 min 1 min 30 
orf 477R 
(CTX-M-1 
group) 
GGT GGC ATA ATT TTT GAA GT (Eckert et al. 2006) 
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Primer 
Name a Sequence (5' – 3') 
Init 
Time 
Ann 
(ºC) 
Ext 
Time Cycles 
Reference 
/amplicon 
(bp) 
FOXMRb CAA AGC GCG TAA CCG GAT TGG 
FOXMF AAC ATG GGG TAT CAG GGA GAT G 
(Perez-Perez 
and Hanson 
2002) 190 
EBCMRb CTT CCA CTG CGG CTG CCA GTT 
EBCMF TCG GTA AAG CCG ATG TTG CGG 
302 
 
ACCMRb TTC GCC GCA ATC ATC CCT AGC 
ACCMF AAC AGC CTC AGC AGC CGG TTA 
346 
 
DHAMRb CCG TAC GCA TAC TGG CTT TGC 
DHAMF AAC TTT CAC AGG TGT GCT GGG T 
405 
CITMRb TTT CTC CTG AAC GTG GCT GGC 
CITMF TGG CCA GAA CTG ACA GGC AAA 
462 
MOXMRb CAC ATT GAC ATA GGT GTG GTG C 
MOXMF GCT GCT CAA GGA GCA CAG GAT 
30 s 52 for 30s 30s 30 
520 
 
a F denotes forward primer, R denotes reverse primer. 
b AmpC PCR (Perez-Perez and Hanson 2002). 
H=A ,C, T; Y=C, T; R= A, G; K=G, T. V=A, C, M=A, C. 
2.2.11.2 ‘Primer Walking’ 
Where sequencing using forward and reverse primers did not completely identify the 
array, primers were designed to ‘primer walk’ the PCR product (Table 2.13). The 
primers were designed using Primer3 Express software and a segment of the known 
sequence was used as input sequence using the programs pre-set protocols for GC 
content, length of primer, Tm, and no self-complementary sequence between 5' and 3' 
end. The PCR product was then sent for sequencing with the newly designed primer 
following identical protocols. 
 
Table 2.13 Primers used for ‘Primer Walking’ 
Primer name a Sequence (5' – 3') Position b Accession No. 
aac(6')IIc.148R  CTA AGA CTT CGT CAA GAG TTG aac(6')-IIc   183-203 AF162771       
aadBF2 GGC CTA ACA ATT CGT CCA aadB        1822-1830 L06418            
ereA49R AGA ATC TCA AAC TCA TTG AA ereA        2747-2767 DQ157752      
aac(6')-IIc   422-440 ICU64PW1F AF162771       CTC GTT GAA CTC CTG TTT A 
 
ICU64PW1R TTT TGT AAA TGA TTG TTG TG ereA        3525-3544 DQ157752       
L12PW1R smr-2      1978-1995 DQ089809      AGC CAA TCT CAA AGA GTC 
CTG TAA TTG AAC CAG CTA AT oxa10      3474-3493 oxa10.80R AY033653      
a ‘F’ and ‘R’ denote the direction of the primer walk, forward or reverse, respectively. 
b Number of base pairs from start of GenBank data base entry 5' – 3'. 
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Table 2.14 Primers and probes used for real-time PCR development 
DNA sequence (5' – 3')  Target  
Real time PCR primers 
mecAF AAA GAA CCT CTG CTC AAC AAG T 
mecAR TGT TAT TTA ACC CAA TCA TTG CTG TT 
mecA 
(88bp) 
nucF AAA TTA CAT AAA GAA CCT GCG ACA 
nucR GAA TGT CAT TGG TTG ACC TTT GTA 
nuc 
(87bp) 
Conventional PCR primers  
CPmecAF AAA ATC GAT GGT AAA GGT TGG C mecA 
(533bp) CPmecAR AGT TCT GCA GTA CCG GAT TTG C 
Probes    
mecAHP2 Hex-CCAGATTACAACTTCACCAGGTTCAACT-BHQ1 mecA 
nucHP1 6-Fam-AATTTAACCGTATCACCATCAATCGCTTT-BHQ1 nuc 
 
 
2.2.12 PCR methods 
 
2.2.12.1 Conventional PCR 
All PCR methods used the following concentrations of reagents (Table 2.15) unless 
otherwise indicated. 1x PCR Buffer, 200 µM of each dNTP and 200 nM of each primer. 
All protocols used 1.5 mM MgCl2 except for the multiplex PCR, aadB, aac(6')-IIc, 
aac(6')-II consensus, aac(3)-II consensus, aac(3)-IIc and aadA2 which used 1.0 mM 
and ERIC PCR which used 2.5 mM. All protocols used 1 U of Taq polymerase except 
for the multiplex PCR, which used 0.5 U, the hep58/hep59 PCR which used 1.5 U and 
ERIC PCR which used 2 U. Multiplex PCR for AmpC followed published primer 
concentrations and 1.25 U Taq was used (Perez-Perez and Hanson 2002).  
All PCR followed a standard PCR protocol of a 5-min hot start. All had a 10-
min final extension step at 72°C. Refer to Table 2.12 for annealing temperatures and 
cycling times. PCR reactions were performed on a PC-960 C cooled thermocycler. 
DNA inocula volume varied depending on whether crude lysate, genomic or 
plasmid DNA was used as template. There were inconsistent and incorrect negative 
results using lysates as template for hep58:hep59 PCR in the initial stage of the study 
(Chapter 6), however genomic DNA (Wizard Kit) performed more reliably and was 
used in this assay throughout. 
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Table 2.15 Conventional PCR Reagents 
Reagent/Marker Source  
BIOTAQ™ DNA Polymerase Bioline London England 
Deoxyribonucleoside triphosphates (dNTPs) Bioline London England 
Magnesium chloride 50mM solution Bioline London England 
10x NH4 Reaction Buffer Bioline London England 
6x Gel Loading Buffer (GLBIII) Bioline London England 
Blue/Orange Loading Dye (6X) Promega co. Milwaukee, Wisconsin 
 
 
2.2.12.2 Real-time PCR reagents used in this work 
OmniMix™ HS lyophilised beads (TakaRa Bio Inc. Otsu, Japan) were used as the 
master mix to optimize the PCR. One reconstituted bead is adequate for two tests, and 
contains 3 U TaKara Hot Start Taq polymerase, 200 μM dNTP, 4 mM, MgCl2 in 25 
mM HEPES buffer, pH 8.0 ± 0.1.and is sufficient for two 25 µL Smart Cycler reaction 
mixtures.  
 
2.2.12.3 Development of real-time PCR protocols 
 
2.2.12.3.1 Titration of primers and probes 
Oligonucleotide primers and probes are listed in Table 2.14; the fluorophors used were 
5’-hexachloro-6-carboxy-fluorescein (HEX)-BHQ1-3’ (mecA) and 5’-6-carboxy-
fluorescein (FAM)-BHQ1-3’ (nuc). Each set of primers and probes were individually 
optimized, using 15 ng of pcMSSA and pcMRSA genomic DNA to titrate the separate 
assays with different annealing and extension temperatures and varying times. Probe 
concentration was then titrated to reduce background fluorescence without unduly 
increasing the number of cycles to positive result. Once individual PCR reactions were 
optimised, the probes were combined and the duplex PCR optimised in the same 
manner, using spiked samples. 
2.2.12.3.2
2.2.12.3.3
 PCR conditions and performance  
All tests were performed on the Smart Cycler II with the detection threshold (level of 
fluorescence above which a sample is considered positive) set at 30 U. Reconstituted 
OmniMix™ HS lyophilised beads were used according to manufacturer's instructions. 
Cycling conditions for clinical blood culture samples, determined in this 
manner, were: (hot start) 95oC 120 s; (step 1) 95oC 10 s; (step 2) 50oC 15 s; (step 3) 
59oC 15 s; 40 cycles. Cycle threshold (Ct), the cycle number at which amplicon 
fluorescence exceeds the preset detection threshold, was recorded for all samples. All 
negative samples were repeated at a 1:10 dilution and any results inconsistent with 
phenotype were repeated at 1:10 and 1:100 dilutions and the phenotype retested. Where 
methicillin-susceptibility results were discordant, a Phoenix Gram positive NMIC/ID-53 
card was inoculated and PCR for mecA was performed, using conventional primers 
(CPmecAF:CPmecAR; Table 2.14), as previously described (Murakami et al. 1991). 
Samples yielding apparent false-negative PCR results were tested for their ability to 
inhibit a positive control. 
During early assay development, the accuracy of PCR amplification was 
confirmed after purification using the Perfectprep Gel cleanup kit by sequencing using 
BigDye® Terminator v 3.1. DNA sequences were analysed by GenBank BLAST 
(NCBI) database search, and sequence alignments performed with EclustalW (via 
ANGIS). 
 
 Sensitivity and specificity 
To determine the limit of detection the linear range (using the correlation coefficient, r2) 
of the Ct for known concentrations of DNA (between 0.005 ng and 5 ng) for the MRSA 
and MSSA controls was identified (where perfect correlation of Ct and concentration is 
r2 = 1.0). Clinical sensitivity and specificity was evaluated by comparing the optimised 
extraction/PCR method with conventional CLSI culture-based methods for 
identification of S. aureus and methicillin resistance, with an additional conventional 
PCR for mecA performed as necessary in consecutive blood cultures containing Gram-
positive cocci suggestive of staphylococci. 
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2.2.13  Electrophoresis 
PCR products were electrophoresed in a Biorad Sub-cell® GT electrophoresis tank 
containing 1x TBE buffer using a 1% agarose gel concentration at 180 V for a period of 
45-60 min depending on the size of gel being electrophoresed. Products from ERIC 
PCR were run on a 2% agarose gel, and RFLP products were run on a 1.5% gel for up 
to two hours to ensure optimal band separation. Plasmid preparations were 
electrophoresed in 0.8% agarose gels in 1x TAE buffer, in an electrophoresis tank 
containing 1x TAE at 80 V for 3-4 h. The TAE buffer was changed midway through the 
electrophoresis. Molecular markers (either 1 Kb ladder, or Hyperladder 1) were run in 
parallel with the PCR product, and gels were then stained in 1 µg mL-1 ethidium 
bromide in 0.5x TBE or TAE. Stained gels were visualised and photographed using an 
UViTec and UViSave transilluminator apparatus and gel photos were printed using a 
Mitsubishi P91 video copy processor.  
                                                                                                  
2.2.14  DNA extraction/cleanup kits 
Table 2.16 DNA extraction/cleanup kits and protocols 
Kit Manufacturer Use in this study Protocol a 
Gerard BIOTECH Spin 
Doctor MB Mini Prep Kit 
Oxford, USA Isolation of plasmid DNA 
from wt and tx strains 
 (Chapter 5) 
 
MagNA Pure LC Total 
Nucleic Acid Isolation 
Kit 
Roche 
Mannheim, 
Germany 
Isolation of genomic DNA 
from Gram-positive and Gram-
negative bacteria from blood 
culture bottles  
(Chapter 3) 
 
Final elution 
volume 100 μL 
 
NucliSens®miniMAG™ 
generic extraction for 
DNA and RNA 
bioMérieux 
Boseind, The 
Netherlands 
Isolation of genomic DNA 
from Gram-positive bacteria 
from blood culture bottles. 
(Chapter 3) 
 
Final elution 
volume 200 μL 
Perfectprep® Gel Cleanup Eppendorf, 
Hamburg 
Germany 
Cleanup of PCR products or 
gel excision for sequencing 
70 µL PCR 
product plus   210 
µL binding buffer 
then usual 
protocol  
 
QIAamp® DNA Mini Kit Qiagen. Hilden, 
Germany 
Isolation of genomic DNA 
from Gram-positive bacteria 
from blood culture bottles and 
from 24-hour HBA culture 
plates (Chapter 3) 
Blood and body 
fluid spin 
protocol, 200 μL, 
eluted in final 
volume 200 μL 
Qiagen DNeasy® Tissue 
Kit 
Purification of 
genomic DNA 
from Gram-
positive bacteria 
Qiagen, Hilden, 
Germany 
Isolation of genomic DNA 
from pure and mixed broth 
cultures of Gram-positive and 
Gram-negative bacterial 
control strains  
(Chapters 3 & 4) 
 
Wizard Genomic DNA 
Purification  kit 
Promega, 
Madison WI, 
USA 
Isolation of genomic DNA 
from Gram-negative bacteria 
for use in PCR (Chapter 6) 
 
a Manufacturers’ protocol followed unless otherwise stipulated 
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2.2.14.1 Genomic and plasmid DNA extraction 
 
2.2.14.1.1
2.2.14.1.2
 DNA extraction for SAM-PCR template 
Pure bacterial DNA was extracted from control strains (Table 2.9) after overnight 
incubation at 35oC on 5% HBA, using the QIAamp® DNA Mini Kit Blood and Body fluid 
spin protocol as per manufacturer’s instructions. DNA was diluted in sterile double-
distilled water to 5 ng/μL and stored at –20oC.  
When positive growth was detected in the BACTEC 9240 in either clinical blood 
culture specimens containing Gram-positive cocci consistent with staphylococci, or from 
“spiked” bottles, 5 mL aliquots were centrifuged (1250 g, 15 min) in a serum separating 
tube and the leucocyte-rich “buffy coat” retained. Direct identification and susceptibility 
plates were inoculated (see 2.10.3) and an aliquot was set aside for DNA extraction. 
Three different extraction protocols were used to extract DNA from blood culture 
bottles: the QIAamp® DNA Mini Kit; the NucliSens mini MAG; and the MagNA Pure LC 
total nucleic acid isolation kit (Table 2.16). For QIAamp®, and the mini MAG, 200 μL of 
“buffy coat” was used and genomic DNA eluted into a final volume of either 200 μL, or 50 
μL where specified. For MagNA Pure extraction, 300 μL MagNA Pure lysis buffer was 
added to 200 μL of well-mixed “buffy coat” and DNA was eluted into a final volume of 
100 uL. Extracted DNA from spiked and clinical specimens was assayed by 
spectrophotometer (A260/280) and stored at -20oC. To test the protocol for routine testing of 
positive blood culture bottles, a standard volume of 5 μL of DNA extract was used as PCR 
template in all reactions.  
 
 Extraction of DNA from broth and plate cultures 
Genomic preparations for all Gram-positive control strains were prepared from overnight 
LB broth cultures using the Qiagen DNeasy® Tissue Kit following the Gram-positive 
protocol for use in Chapter 4. 
Overnight LB broth cultures or 24-hour HBA plate cultures of Gram-negative 
control strains and clinical isolates were extracted either using the Wizard Genomic DNA 
purification kit or the Qiagen DNeasy® Tissue kit following the Gram-negative protocol 
for use in Chapters 4-6. Where broth contained a mixed growth of both Gram-positive and 
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Gram-negative bacteria (Chapter 4), the Qiagen DNeasy® Tissue kit Gram-positive 
protocol was used. 
 
2.2.14.1.3
2.2.15
 Plasmid extraction 
One to three colonies from a fresh 24-hour culture were inoculated into 10 mL of LB broth 
plus 10 µg/mL gentamicin and incubated overnight at 35° C on a rotary shaker. Those 
strains not resistant to gentamicin were incubated without selection. Four mL of the 
overnight broth was centrifuged to obtain a pellet, the supernatant discarded, and standard 
protocols for the Gerard BIOTECH Spin Doctor MB Mini Prep Kit were used. 
 
2.2.14.2 DNA quantitation 
DNA was tested using the BioPhotometer (Eppendorf) ddDNA program using a 55 µL 
aliquot. If the reading was too high, the cuvette was rotated 90 degrees to shorten the 
length of the light path, and the resulting DNA concentration multiplied by 5. Where 
necessary, DNA was diluted 1:10 in sterile distilled water and the result multiplied by the 
dilution factor. 
 
  Post-PCR sequence and molecular analysis 
Post-PCR products for sequencing were prepared using the Perfectprep® Gel Cleanup Kit 
following standard protocols. Where only one band was visible on the gel the PCR product 
was used (70 µL) or if multiple bands existed, the bands were excised then standard kit 
protocols were followed. Post cleanup product (5 µL) was visualized on a 1% agarose gel 
and compared to Hyperladder 1 to check size and DNA concentration and was then stored 
at -20°C. A total volume of 12 µL of product including 3.9 pmol of primer was sent for 
sequencing at the Westmead Millennium Institute BigDye Terminator v 3.1 system. 
Programs used to analyse sequence data included EditSeq™ and Megalign™ 
Expert Sequence Analysis Software from DNA STAR, Inc. (Madison, Wisconsin). Web 
ANGIS; Web FM from ANGIS Bioinformatic services (Sydney, Australia) was also used. 
PCR products were sequenced then matched against the GenBank NCBI database using 
BLASTN (http://www.ncbi.nlm.nih.gov/BLAST/. Alignments were performed with 
EclustalW (via ANGIS).  
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2.2.16  Mating experiments 
 
2.2.16.1 Preparation of donor and recipient strains 
Conjugation experiments with the rifampicin-resistant aminoglycoside-susceptible strain of 
E. coli UB5201Rf or the nalidixic acid-resistant aminoglycoside-susceptible strain of E. 
coli DH5α were performed by a filter-mating method. 
The recipient strains were spread on rifampicin (80 µg/mL) or nalidixic acid (25 
µg/mL) containing agar plates and incubated overnight at 35°C. Four loopfuls of the 
recipient strains were suspended in 1 mL of saline, washed twice and resuspended in 200 
µL of saline. 100 µL of dilutions at 1:1000, 1:10,000, and 1; 100,000 were spread over 
three separate rifampicin-containing plates for E. coli UB5201Rf and nalidixic acid-
containing plates for E. coli DH5α. The remaining pooled recipient saline suspension was 
used for mating.  
The donor bacterial strains that were gentamicin-resistant were grown overnight 
on gentamicin-containing plates at 35°C then inoculated into 10 mL of nutrient broth with 
gentamicin (10 µg/mL) and incubated overnight on a rotary shaker at 150 rpm. After 
incubation, 1 mL of each broth culture was transferred to a 1.5 mL microfuge tube and 
centrifuged at 10,000 g on a Heraeus Biofuge for 5 min. The supernatant was discarded 
and the pellet washed twice with 1 mL of sterile saline, then finally resuspended in 200 µL 
of sterile saline.  
100 µL of the appropriate donor strain was gently mixed with 100 µL of the 
appropriate recipient strain. A nitrocellulose filter was placed on the surface of a blood 
agar plate and four drops (25 µL each) of the mixture were inoculated on to the filter. The 
plates were incubated in the inverted position at 37°C for four h.  
1 mL of saline was added to each plate and the growth dislodged using a bent 
sterile Pasteur pipette. This was then transferred to a 1.5 mL microfuge tube, and 
centrifuged at 10,000 g for 5 min. The supernatant was discarded, and the pellet 
resuspended in 200 µL saline. 100 µL was used to make 1:100 and 1:1,000 dilutions. The 
dilutions and the remaining 100 µL of neat mix were spread over the surface of rifampicin-
gentamicin-containing plates or nalidixic acid-gentamicin-containing plates. 
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The plates were then incubated overnight at 35°C under aerobic conditions. The recipient 
strains were treated similarly and colony counts performed so that transfer frequencies 
could be calculated and expressed in terms of the number of tx obtained/recipient cell. 
 
2.2.16.2 Screening of transconjugant clones 
After overnight incubation the antibiotic-containing plates were screened for 
transconjugants by inoculation of colonies onto fresh rifampicin-gentamicin-containing 
plates or nalidixic acid-gentamicin-containing plates. 
Potential transconjugants were further tested where possible using Orientation 
CHROMagar plates (Dutec Diagnostics), which differentiate donor strains of Enterobacter 
spp. and Klebsiella spp. by colour. Enterobacter spp. and Klebsiella spp. (wt) grow as blue 
colonies on this agar whereas the two E coli recipient strains appear either as pink 
(UB5201Rf) or white colonies (DH5α). Pink colonies on CHROMagar plus rifampicin-
gentamicin or white colonies on nalidixic acid-gentamicin indicate transconjugants. 
Confirmation of potential transconjugants was by performing identification and 
susceptibility testing. Plasmid extraction was performed on all transconjugants and they 
were stored in 20% glycerol nutrient broth at -20°C. 
To identify transmission of genetic elements and to confirm if the transconjugants 
carried cassette arrays, hep58/hep59 PCR was performed on all tx strains.  
 
2.2.17 Restriction fragment length polymorphism (RFLP) 
Where necessary, RFLP was performed on PCR product of the same length from different 
isolates to determine if the products were identical. The restriction enzyme cutter was 
chosen by taking known sequence from one isolate and selecting the appropriate enzyme 
from the website (http://tools.neb.com/NEBcutter2/index.php). Incubation conditions and 
choice of NEB buffer followed protocols set out in the New England Biolabs 2005-06 
catalogue and technical reference. Protocol volumes were as follows; 10 µL PCR product, 
2 µL NEB 10x buffer, 1 µL restriction enzyme, 7 µL water. Incubation for 1 h was 
followed by inactivation at the recommended temperature for 20 min. The total volume (20 
µL) was run on a 1.5% agarose gel at 150 V for 1 h. 
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